



**Kingdom of Saudi Arabia  
Saudi Health Council  
Saudi Cancer Registry**

**Cancer Incidence Report  
Saudi Arabia  
2013**

**June 2016**



**Prepared by**

Mrs. Amal Nasser Al.-Madouj  
Mr. Zeyad Saeed Alshahrani  
Mr. Ahmed Ibrahim Alrawaji  
Mr. Mohammed Saleh Hayder  
Ms. Mona Mohammed Al-Shridah  
Ms. Tahani Husssin Al-Shamrani

**Reviewed by**

Dr. Ali Saeed Al-Zahrani  
Dr. Hind Mohammed Al-Mutlaq  
Dr. Amer Naeem Radwi  
Dr. Shouki Mohammed Bazarbashi



ISSN: 1658 - 0559

## Foreword

I'm delighted to present to you the Annual Cancer Incidence Report 2013, which is a collaborative effort achieved by the team of Saudi Cancer Registry (SCR). The registry is considered one of the first national registries in the kingdom. It commenced its duties under the umbrella of King Faisal Specialist Hospital in 1992 and was transferred to Saudi Health Council (SHC) in 2014 to resume its activities under the National Health Registries Department. The registry aims at being the foundation stone in fighting against cancer by providing accurate data regarding cancer cases in the kingdom and by gathering data from various health sectors through the registry's channels represented in the regional offices and their distributed branches across the kingdom.

National cancer registration started in January 1994, by gathering cancer data from different health sectors across the kingdom, where all diagnosed cancer cases information in hospitals are registered, coded and entered through a computerized system (CanReg). The data analysis and the periodic preparation of the reports is basically done at the main office. The reports demonstrate the geographic and demographic distribution of different types and stages of diagnosed cancer cases while the statistics illustrate the changes in rates of cancer over the past twenty years.

Taking the quality of the data registered to its best levels, we have trained our tumor registrars inside the Kingdom and abroad in the most competent and experienced cancer registration centers. The registry also holds workshops periodically on Principles of Cancer Registration for candidates from the health affairs and other health sectors around the kingdom. Such programs aim at empowering the capabilities of trainees in this vital area, where their role lies in finding cases from the affiliated hospitals to facilitate cancer registration process and to provide accurate statistics about the disease, which consequently reflects the trend of cancer in the kingdom. Saudi Cancer Registry has contributed to the international reports with the International Agency for Research on Cancer (IARC) periodically, such as: Cancer Incidence in Five Continents Volume IX, and Childhood Cancer Incidence volume III.

Saudi Cancer Registry collaborates with the Gulf Cancer Center for Cancer Control and Prevention and other specialized centers, to benefit from regional expertise in the fields of cancer registration and to strengthen its training and development programs. The registry has participated in many awareness campaigns and scientific activities in cooperation with different health sectors.

The Annual Reports help decision-makers in planning for establishing new cancer treatment centers, as well as developing new prevention programs. It is worth mentioning that Cancer data is available to all researchers and competent authorities upon request and by filling a certain form.

General Secretary of Saudi Health Council

Dr. Yagob Al-Mazrou

## **Introduction**

This is the seventeenth incidence report published by the Saudi Cancer Registry. Previous publications include the Incidence Reports for the years 1994 -1996,1997 -1998,1999 -2000 and yearly until 2012. The structure of this report can be outlined as follows:

### **Part I- Materials and Methods**

This part of the report contains information about the background of the Saudi Cancer Registry and methods used in collecting and analyzing the data. We present the basics of coding and classification of tumor topography, morphology and extent of disease at the time of diagnosis. Also we describe the software programs we have used to analyze the data.

### **Part II- Overview of Cancer Incidence**

Part II contains figures and tables that show overall cancer incidence in Saudi Arabia for the year 2013. We present these figures and tables mainly by sex and in certain areas we have it analyzed by different age groups. There are bar charts representing the age distribution of cancer incidence for the year 2013 among Saudis by sex and age groups. We present incidence and morphology tables for the most common types of cancers among adults and children. In addition, tables, list the total number of cases, the Age-Standardized Incidence Rate (ASR) per 100,000 population, Crude Incidence Rate (CIR) and Cumulative rates by primary site and sex. Separate bar charts depict the most common types of cancer, by sex.

### **Part III- Cancer Incidence for Most Common Sites 2013**

In this part the incidence of the most common cancers among Saudi males and females are outlined. A standardized layout presents data for all patients and for both sexes where applicable. For each selected site the number and the percentage of all newly diagnosed cases for the year 2013, the ASR for each sex and the specific cancer rank for both sexes are presented. In addition, ASR for the specified cancer among Saudis is compared with ASR among other populations from selected countries

### **Part IV-Cancer Incidence among Non- Saudis**

This part presents the incidence of cancer cases among Non-Saudis including the most common types of cancer. The analysis of the Non-Saudis is performed separately due to the nature of the expatriate population in Saudi Arabia in which a large part of the population, particularly among males, falls in the 25 - 44 age groups.

### **Part V-Incidence Tables**

Contains the following detailed tables for all newly diagnosed cancer types among Saudis and Non-Saudis for 2013.

- Distribution of cancer cases among Saudis by age group and sex.
- Distribution of cancer cases among Non Saudis by age group and sex.
- Cancer Incidence (per 100,000 populations) among Saudis by age group and sex.
- Cancer Incidence (per 100,000 populations) among Non-Saudis by age group and sex.
- Age-standardized incidence rate and relative frequencies among Saudis by cancer site, sex.

### **Arabic Summary**

Contains Arabic Summary of Cancer Statistics in Saudi Arabia for the Year 2013.

## Table of Contents

Foreword .....	5
Introduction .....	6
<b>PART I</b>	
<b>MATERIALS AND METHODS</b>	
Background on Saudi Arabia .....	10
Saudi Cancer Registry .....	10
Definitions Of Statistical Terms .....	13
<b>PART II</b>	
<b>OVERVIEW OF CANCER INCIDENCE 2013</b>	
Reported Cancer Incidence Cases in Saudi Arabia, 2013 .....	16
Cancer Incidence among Saudi Nationals, 2013 .....	17
Adult Cancers in Saudi Arabia, 2013 (>14 years) .....	21
Childhood Cancers in Saudi Arabia, 2013 ( $\leq$ 14 years) .....	22
International Comparison of Age-Standardized Incidence Rates for all Types and Cancer by sex .....	25
<b>PART III</b>	
<b>CANCERS INCIDENCE FOR MOST COMMON SITES 2013</b>	
Cancers Incidence for Most Common Sites, 2013 .....	28
Female Breast Cancer (C50) .....	29
Colorectal (C18-C20) .....	31
Thyroid (C73) .....	33
Non-Hodgkin Lymphoma (C82-C85; C96) .....	35
Leukemia (C91-C95) .....	37
Liver (C22) .....	39
Lung (C33-C34) .....	41
Hodgkin Disease (C81) .....	43
Stomach (C16) .....	45
Kidney (C64) .....	47
References .....	49
<b>PART IV</b>	
<b>CANCER AMONG NON-SAUDIS 2013</b>	
Cancer among Non-Saudi Population 2013 .....	52
<b>PART V</b>	
<b>INCIDENCE TABLES</b>	
Table 5.1.1 Number of Cancer Cases among Saudi Males by Primary Site and Age Groups, 2013 .....	56
Table 5.1.2 Number of Cancer Cases among Saudi Females by Primary Site and Age Groups, 2013 .....	57
Table 5.1.3 Age-Specific Incidence Rate (AIR), Age-Standardized Incidence Rate (ASR) among Saudi Males (per 100,000) by Primary Site and Age Groups , 2013 .....	58

Table 5.1.4 Age-Specific Incidence Rate (AIR), Age-Standardized Incidence Rate (ASR) among Saudi Females (per 100,000) by Primary Site and Age Groups, 2013 .....	59
Table 5.4.1 Number of Cancer Cases among Non-Saudi Males by Primary Site and Age Groups, 2013 .....	60
Table 5.4.2 Number of Cancer Cases among Non-Saudi Females by Primary Site and Age Groups, 2013 .....	61
Table 5.4.3 Age-Specific Incidence Rate (AIR), Age-Standardized Incidence Rate (ASR) among Non-Saudi Males (per 100,000) by Primary Site and Age Groups , 2013 .....	62
Table 5.4.4 Age-Specific Incidence Rate (AIR), Age-Standardized Incidence Rate (ASR) among Non-Saudi Females (per 100,000) by Primary Site and Age Groups, 2013 .....	63
Table 5.5.1 Number Of New Cases by Primary Site and Years among Saudi Males, 1994- 2013 .....	64
Table 5.5.2 Number Of New Cases by Primary Site and Years among Saudi Females, 1994- 2013 ..	65
Table 5.5.3 Age Standardized Incidence Rate by Primary Site and Years among Saudi Males, 1994 -2013 .....	66
Table 5.5.4 Age Standardized Incidence Rate by Primary Site and Years among Saudi Females, 1994 -2013 ...	67
<b>Acknowledgment</b> .....	69
<b>Arabic Summary</b> .....	72 - 74

**PART I**  
**MATERIALS AND METHODS**

## Background on Saudi Arabia

Saudi Arabia is a vast country extending over fourfifths of the Arabian Peninsula. It stretches from the Arabian Gulf in the east to the Red Sea in the west. It is approximately 2,149,700\* square kilometers in area and is divided into 13 administrative regions (Figure 1.1).

Figure 1.1 Administrative Regions of Saudi Arabia



The Saudi national population for year 2013 was 20,180,080\*\* Of these 10,181,018 (50.2%) were males and (49.8%) 10,090,040 were females. The Non-Saudi population in 2013 was 9,723,214\*\*; of these 6,643,278 (68.3%) were males and 3,079,936 (31.7%) females. Figures 1.2 and 1.3 show the Saudi and Non- Saudi population pyramids by sex and age group respectively.

Figure 1.2 Population Pyramids of Saudis (%) by Sex and Age Group, 2013





Figure 1.3 Population Pyramids of Non-Saudis (%) by Sex and Age Group, 2013



## Saudi Cancer Registry

The Saudi Cancer Registry (SCR) is a population based registry established in 1992 under the authority of the Ministry of Health (MOH). In 2014 SCR was moved to Saudi Health Council under department of National Registries.

## Objectives

The primary goal of the SCR is to define the population - based incidence of cancer in Saudi Arabia. Another objective is to support the early detection programs and cancer screening programs, as well as cancer research projects through providing accurate cancer data.

## Organizational Structure

Representatives from MOH, King Faisal Specialist Hospital and Research Center, and Medical Services Departments of the Ministry of Defense and Aviation, Ministry of Interior, Ministry of National Guard, King Saud University. Representatives are charged with the responsibility of overseeing the SCR's establishment, defining demographic and cancer related data to be collected, approving data requests, and reporting findings, as well as disseminating information collected while ensuring the confidentiality of all data reported to the SCR.

Additionally, five regional branches and five hospital based offices were set up to ensure comprehensive data collection from all over the Kingdom (Figure 1.4).

\* Source :Demographic and Health Indicators for Countries of the East Meditrrtanean, WHO, Regional Office for the EM,1999

\*\* Source : Central Department of Statistics & Information, Ministry of Economy and Planning

## Regional Offices

1. Central Region : King Fahad Medical City in Riyadh, covering Riyadh, Qassim, and Hail Health Regions.
2. Eastern Region : King Fahad Hospital of the University, Al Khobar, covering Dammam, AlAhsa, and Hafr Al-Batin Health Regions.
3. Western Region : East Jeddah General Hospital, Jeddah, covering Jeddah, Makkah, Taif and Qunfudah Health Regions.
4. Southern Region : Asir Central Hospital, Abha, covering Asir, Baha, Najran, Jazan and Bisha Health Regions.
5. Madinah / Northern Region : Maternity and Children Hospital, Madinah, covering Madinah, Tabuk, Jouf and Northern Health Regions.

## Offices at the Medical Service Division or Oncology Department of the following establishments

6. King Faisal Specialist Hospital & Research Centre, Riyadh
7. Ministry of Defense and Aviation, Armed Forces Hospitals, Riyadh
8. Ministry of Interior, Security Forces Hospital, Riyadh
9. Ministry of National Guard Hospitals, King Abdulaziz Medical City, Princess Norah Oncology Center, Jeddah.
10. King Khalid University Hospital, Riyadh.


Each of the SCR office operates under the supervision of directors who are responsible for the daily management. Staffing consists of tumor registrars and secretarial staff. The SCR Main Office indirectly supervises the regional offices to ensure accuracy and quality of data collected from all regions. Quality control processes include verification of site, morphology, and staging information as well as case linkage (tumor and patient), and consolidation of data. The Main Office also

prepares annual reports for dissemination of information to the medical community, government establishments, international organizations and the media.

## Format

The format of the current report is similar to the previous reports.

**Figure 1.4 Organizational Chart of the Saudi Cancer Registry**



## Data Management

A ministerial decree has categorized cancer as a mandatory notifiable disease. This ensures the opportunity for comprehensive data collection. The SCR strives for full access to cancer data from all Ministry of Health, governmental and private hospitals, as well as clinics and laboratories throughout the Kingdom. Cancer data are abstracted from patients' medical records, based on clinical and/or histopathological diagnosis, by SCR-trained cancer registrars.

The data abstract includes personal identification (name, ID Number, sex, age), demographic information (address, telephone number, nationality), and tumor details (diagnosis date, primary site, histology, behavior, grade, stage, basis of diagnosis). The primary site (topography) and histology (morphology) of the malignancies are identified and coded according to the International Classification of Diseases for Oncology 3rd Edition (ICDO-3), published by the World Health Organization (WHO), 2000. Effective from year 2001, changes were made in coding of cancer types and behaviors as well as staging according to International guidelines. The new SEER Summary Stage 2000 guidelines should result in increased accuracy and consistency in the coding of stage. There are some differences in the timing rules for determining stage and some sites are coded differently using the new guidelines. However, the new criteria and guidelines should improve the usefulness of staging as a predictor of prognosis and survival as the changes reflect a new understanding of the natural history of cancer. The new guidelines, SEER Summary Stage Manual 2000, are available on the web at :<http://seer.cancer.gov/tools/ssm/>

Cases diagnosed on or after 01 January 2008 are classified according to the updated ICD-O-3. Improvements in the understanding of cancer pathology over the last decade are reflected in the changes to ICD-O-3. While there have not been any changes in the primary site codes, there are significant changes regarding histology (cell types). Leukemias and lymphomas, particularly are affected. Some cases that were previously considered benign are now counted as malignant. Also small number of cancers that

were previously coded as borderline tumors are now considered benign. Counts of ovarian cancers, lymphomas and leukemias as well as some hematopoietic diseases will change due to changes in either report ability or definition. However, as with the new staging guidelines, the ICD-O changes reflect advances in the understanding of the pathology and behavior of cancers.

It should be noted that ICD-O-3 codes are converted to ICD-10 for analysis purposes. Since the WHO has not yet converted the ICD-10 hematopoietic disease behavior changes, our software, Can- Reg 4.33, cannot include these cases for analysis and they have been excluded. Every effort is made to accurately code patient and tumor information, to ensure that all data can be reviewed, linked, and consolidated, as appropriate, so that each malignancy is counted only once for statistical analysis. The computer software programs used for data entry and incidence tables output are CanReg 4.33, developed by the International Agency for Research on Cancer (IARC), Lyon, France.

The second part of the report includes the overall cancer incidence in Saudi Arabia and the relevant epidemiological and clinic pathological details for the 10 most common cancers among Saudi nationals for the year 2013. For each cancer site, the number and the percentage of all newly diagnosed cases for the year 2013, the age-standardized incidence rate (ASR) per 100,000 populations for each sex, and the specific cancer rank in comparison to all cancers for both sexes are presented. Useful international statistics for the specified cancer include the ranking of the cancer worldwide. The relevant data incorporate details for all patients presented over the year 2013. For each cancer there are five figures:

1. An arithmetic line graph represents the agespecific incidence rate (AIR) for all age groups at five-year intervals. The graph is plotted by sex, where applicable.
2. A table lists the percentages of the most common histology sub-types for each specific cancer.

3. A pie chart shows the distribution of the clinical stages of each cancer such as localized, regional, distant metastasis and unknown.

4. A bar chart shows regional distribution of ASR for particular cancer across the administrative regions by males and females.

5. A bar chart shows comparison of age-standardized incidence rate (ASR) for each cancer type in Saudi Arabia with ASR in selected countries.

### Notification

The data included in this report were abstracted up to December 2015. The incident cases which were identified after this date (late reporting) will be noted in subsequent incidence reports. It is anticipated that the number of late-reported cases will decrease as case ascertainment processes are improved. Moreover we don't have up to date statistics because we have to wait until all of the data from the regional cancer branches in Saudi Arabia has been collected before we can publish the annual incidence report. Also, the process of registering a cancer is complicated and there are a number of processes in place to ensure the data is of a high quality. This means there is usually a delay of around 2 - 3 years before the data is complete enough to be published.

### Definitions of Statistical Terms

#### Age-Specific Incidence Rate (AIR)

The number of cancer cases occurring during a specific period in a population of a specific age and sex group, divided by the number of midyear population of that age and sex group.

#### Age-Standardized Rate (ASR)

The Age-standardized rate is a summary measure of a rate that a population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with respect to age structure. The most frequently used standard population is the World Standard Population (see below). The calculated incidence is known as the World Standardized Incidence Rate. The rate is expressed per 100,000 populations.

### Crude Incidence Rate (CIR)

The crude incidence rate for a cancer site is the total number of cases registered as a proportion of the total population. It denotes the approximate number of cases occurring in each 100,000 individuals. All rates are thus, expressed as per 100,000 population. Cancer rates vary greatly with age and the crude rate is strongly influenced by the demographic structure of the population. Hence, if the population structure changes over time the crude rate over that period may be artificially altered. It is not appropriate to compare crude rates across geographical areas of cancer registries with different population age structures. Therefore, in order to assess time trends in registration data or compare incidence across geographical areas or between registries it is necessary to first standardize the rates with respect to age.

Age Class	Population
0 - 4	12,000
5 - 9	10,000
10 - 14	9,000
15 - 19	9,000
20 - 24	8,000
25 - 29	8,000
30 -34	6,000
35 - 39	6,000
40 - 44	6,000
45 - 49	6,000
50 - 54	5,000
55 - 59	4,000
60 - 64	4,000
66 - 69	3,000
70 - 74	2,000
75+	2,000
<b>Total</b>	<b>100,000</b>

\* Doll R. Payne P. Waterhouse J. Cancer Incidence in Five Continents Vol. I. International Union against Cancer. 1966

### **Cumulative Incidence rate**

Cumulative incidence rate is the probability or risk of individuals developing the disease during a specified period. For cancer, it is expressed as the number of new born children (out of 100, or 1000) who would be expected to develop a particular cancer before the age of 65 (or 70, or 75) if they had the rates of cancers currently observed. Like the age standardized rate, it permits comparison between populations of different age structures. In this report the age ranges 064- and 074- years are used. The cumulative rate is the summation of the cancer age-specific rates; which are computed for five-year age intervals. The cumulative rate is five times the sum of the age-specific rates calculated over the five-year age groups.

### **ICD - 10**

The World Health Organization's International Classification of Diseases, tenth edition.

### **ICD - O - 3**

The World Health Organization's International Classification of Diseases for Oncology, 3rd Edition has been the standard coding system for neoplasms for over 25 years. The coding system includes a four character code for primary site, a four-digit numeric code for cell type, one-digit code for behavior and a one-digit code for tumor aggressiveness (grade).

### **Incidence rate**

An incidence rate is defined as the rate at which a new event occurs in a population. It is calculated as the number of new cases of disease arising in a population over a defined time period, divided by the population at risk of developing that disease.

### **Mean**

The simple mathematical average of two or more numbers.

### **Median**

The midpoint of the range numbers that are arranged in order of value.

### **Metastasis**

Metastasis is the distant spread of cancer from its original site to other organs of the body, including lymph nodes, skeletal and or visceral organs.

### **Range**

It is the difference between the maximum and minimum values in a set of observations.

### **Rank**

This measure reflects the importance of a specific cancer site relative to other sites, in terms of the number of registrations. Ranking illustrates the most and least frequent cancer sites in a population according to their frequency.

### **Ratio**

It is the relation between two quantities. The first quantity as numerator and the second as denominator

### **Relative Frequency**

This statistic is defined as the number of specific cancer cases registered relative to the total number of all cancer. It is expressed as a percentage.

### **Summary Stage**

Staging is the grouping of cancer cases into broad categories based on the extent of disease.

**PART II**  
**OVERVIEW OF CANCER INCIDENCE**  
**2013**

## Reported Cancer Incidence Cases in Saudi Arabia, 2013

Between January 01 and December 31, 2013, the total number of cancer incident cases reported to the Saudi Cancer Registry (SCR) was 15,653. Overall cancer was more among women than men; it affected 7,359 (47.0%) males and 8,294 (53.0%) females. Total of 11,645 cases were reported among Saudis, and 3,356 among Non- Saudis and 232 of Unknown Nationality.

The total number of cases excluded from analysis include 232 cases of Unknown Nationalities, other exclusions were 343 In situ cases; the current software program CanReg-4 version 4.33, does not include in situ cases in the statistical analysis. Also, 77 were ICD-O-3 coded cases that failed to convert to ICD-10 codes as described in the Data Management. This puts the total number of exclusions from the analysis as 652 cases. Table 2.1 illustrates the distribution of the cases by sex, and nationality.

Diagnosis of malignancy was confirmed Histologically in 85.3% of the cases, and Hematological and Cytologically in 5.6% of cases. Clinically confirmed cases were 0.1%, Laboratory 0.1% Radiologically confirmed cases were 2.7%, cases confirmed by Death Certificate were 2.1% and the method of diagnosis was unknown for 0.4% of the cases (Table 2.2).

Total of 15,001 cases were analyzed, of which 11,645 (77.6%) were Saudis and 3,356 (22.3%) were Non-Saudis. Among Saudis 5,281 (45.3%) were male and 6,364 (54.7%) were female. The female to male ratio was 120:100. The crude incidence rate (CIR) of all cancers among Saudis population was 57.5 /100,000 (51.9 /100,000 among males and 63.1 /100,000 among females). The overall age-standardized incidence rate (ASR) for Saudis was 79.1 /100,000 in males and 89.4 /100,000 in females.

For all sites, the age-specific incidence rate (AIR) increased with age for both Saudi males and females. The median age at diagnosis for men was 58 years; range (0 -122) and 51 years for women; range (0 - 116).

**Table 2.1 Distribution of cancer cases in Saudi Arabia by Nationality and Sex, 2013**

Saudis						Unknown Nationality*			Non-Saudis					
Analyzed			Non-analyzed*						Analyzed			Non-analyzed*		
Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
5281	6364	11645	140	172	312	119	113	232	1759	1597	3356	60	48	108









**Table 2.2 Basis of Diagnosis of Cancer Cases, 2013**

Basis of Diagnosis	No.	%
Histology of primary	9927	85.3
Cytology/ Haematological	648	5.6
Histology of metastases	433	3.7
Medical Imaging (Xray,US)	313	2.7
DCO (Death Certificate )	243	2.1
Unknown	53	0.4
Clinical	14	0.1
Laboratory test (Tumor Marker)	12	0.1
Surgery	2	0
Total	11645	100

## Cancer Incidence among Saudi Nationals, 2013

As explained earlier the total numbers of cancer cases analyzed among Saudis during the year 2013 was 11,645. Following are figures presenting the percentage distributions of (cancer incidence) and most frequent types of cancers among Saudis by sex and age-group.

**Figure 2.1 Percentage Distribution of Cancer Incidence among Saudis by Sex according to Age Group, 2013**



**Figure 2.2 Percentage Distribution of Most Frequent Types of Cancer by Sex and Age-Groups among Saudis, 2013**


**Table 2.4 Most Common Cancers among Saudis, 2013 for All Ages**

Sites	No.	%
Breast	1874	16.1
Colorectal	1387	11.9
Thyroid	884	7.6
NHL	746	6.4
Leukemia	684	5.9
Liver	495	4.3
Lung	435	3.7
Hodgkin disease	393	3.4
Stomach	316	2.7
Kidney	313	2.7

**Table 2.5 Most Common Cancers among Saudis by sex, 2013**

Male	5281	%	Female	6364	%
Colorectal	736	13.9	Breast	1853	29.1
NHL	435	8.2	Thyroid	702	11.0
Leukemia	402	7.6	Colorectal	651	10.2
Liver	339	6.4	NHL	311	4.9
Lung	326	6.2	Corpus Uteri	289	4.5
Prostate	306	5.8	Leukemia	282	4.4
Hodgkin disease	239	4.5	Ovary	194	3.0
Bladder	227	4.3	Liver	156	2.5
Stomach	195	3.7	Hodgkin disease	154	2.4
Kidney	193	3.7	Brain	128	2.0

Figure 2.3 Age-Specific Incidence Rate (AIR) for All Cancer among Saudis, 2013



**Table 2.6 Number, Percentage, ASR, CIR and Cumulative Rates (per 100,000) of New Cases by Primary Site and Sex among Saudis, 2013**

ICD-10	Site	Male						Female					
		No.	%	Crude	ASR	Cumulative Rate		No.	%	Crude	ASR	Cumulative Rate	
				Rate	World	0-64	0-74			Rate	World	0-64	0-74
All	All sites Total	5281	100.0	51.9	78.5	39.5	86.0	6364	100	63.1	89.4	60.2	98.7
Not C44	All sites but C44	5075	96.1	49.9	75.2	38.4	82.8	6247	98.2	62	87.6	59.4	96.8
C00	Lip	8	0.2	0.1	0.1	0.1	0.1	7	0.1	0.1	0.1	0.0	0.2
C01-C02	Tongue	49	0.9	0.5	0.8	0.3	0.9	46	0.7	0.5	0.7	0.4	0.8
C03-C06	Mouth	45	0.9	0.4	0.7	0.3	0.9	51	0.8	0.5	0.8	0.4	1.0
C07-C08	Salivary glands	23	0.4	0.2	0.3	0.2	0.3	15	0.2	0.1	0.2	0.1	0.3
C09	Tonsil	3	0.1	0	0.1	0.0	0.1	2	0	0	0	0.0	0.0
C10	Other Oropharynx	3	0.1	0	0	0.0	0.1	0	0	0	0	0.0	0.0
C11	Nasopharynx	136	2.6	1.3	1.8	1.3	2.0	47	0.7	0.5	0.6	0.5	0.6
C12-C13	Hypopharynx	10	0.2	0.1	0.2	0.1	0.1	16	0.3	0.2	0.2	0.1	0.3
C14	Pharynx unspc.	5	0.1	0	0.1	0.0	0.0	3	0	0	0	0.0	0.0
C15	Oesophagus	66	1.2	0.6	1.1	0.4	1.0	49	0.8	0.5	0.8	0.3	1.1
C16	Stomach	195	3.7	1.9	3.3	1.4	3.8	121	1.9	1.2	1.8	1.0	1.9
C17	Small intestine	45	0.9	0.4	0.7	0.3	0.8	16	0.3	0.2	0.2	0.1	0.3
C18	Colon	444	8.4	4.4	7	4.3	8.5	411	6.5	4.1	6.4	4.3	7.5
C19-C20	Rectum	292	5.5	2.9	4.7	2.8	5.7	240	3.8	2.4	3.7	2.3	4.7
C21	Anus	17	0.3	0.2	0.2	0.2	0.3	7	0.1	0.1	0.1	0.1	0.1
C22	Liver	339	6.4	3.3	5.9	2.3	7.6	156	2.5	1.5	2.6	1.2	3.3
C23-C24	Gallbladder etc.	77	1.5	0.8	1.3	0.7	1.5	97	1.5	1	1.7	0.8	2.0
C25	Pancreas	130	2.5	1.3	2.2	1.0	2.7	103	1.6	1	1.7	0.9	2.0
C30-C31	Nose, sinuses etc.	6	0.1	0.1	0.1	0.1	0.1	7	0.1	0.1	0.1	0.1	0.1
C32	Larynx	78	1.5	0.8	1.3	0.7	1.5	25	0.4	0.2	0.4	0.3	0.5
C33-C34	Bronchus,Lung	326	6.2	3.2	5.5	2.3	6.7	109	1.7	1.1	1.8	1.1	2.3
C37-C38	Other Thoracic organs	21	0.4	0.2	0.2	0.2	0.2	19	0.3	0.2	0.3	0.2	0.3
C40-C41	Bone	63	1.2	0.6	0.6	0.3	0.5	63	1	0.6	0.6	0.4	0.4
C43	Melanoma of Skin	13	0.2	0.1	0.2	0.1	0.3	10	0.2	0.1	0.2	0.1	0.2
C44	Other Skin	206	3.9	2	3.3	1.2	3.2	117	1.8	1.2	1.8	0.8	1.9
C45	Mesothelioma	7	0.1	0.1	0.1	0.0	0.2	2	0	0	0	0.0	0.1
C46	Kaposi sarcoma	24	0.5	0.2	0.4	0.1	0.3	4	0.1	0	0	0.0	0.0
C47,C49	Connective,Soft tissue	85	1.6	0.8	1	0.5	0.9	65	1	0.6	0.8	0.6	0.7
C50	Breast	21	0.4	0.2	0.3	0.2	0.4	1853	29.1	18.4	25.5	20.3	27.8
C51	Vulva	-	-	-	-	-	-	11	0.2	0.1	0.1	0.1	0.1
C52	Vagina	-	-	-	-	-	-	5	0.1	0	0.1	0.1	0.2
C53	Cervix Uteri	-	-	-	-	-	-	104	1.6	1	1.5	1.2	1.7
C54	Corpus Uteri	-	-	-	-	-	-	289	4.5	2.9	4.9	3.5	6.2
C55	Uterus unspc.	-	-	-	-	-	-	54	0.8	0.5	0.9	0.6	1.0
C56	Ovary	-	-	-	-	-	-	194	3	1.9	2.7	1.9	2.9
C57	Other Female Genital	-	-	-	-	-	-	12	0.2	0.1	0.2	0.1	0.4
C58	Placenta	-	-	-	-	-	-	11	0.2	0.1	0.1	0.1	0.1
C60	Penis	2	0.0	0	0	0.0	0.0	-	-	-	-	-	-
C61	Prostate	306	5.8	3	5.5	1.7	6.0	-	-	-	-	-	-
C62	Testis	94	1.8	0.9	0.9	0.6	0.7	-	-	-	-	-	-
C63	Other male genital	3	0.1	0	0.1	0.0	0.1	-	-	-	-	-	-
C64	Kidney	193	3.7	1.9	2.9	1.5	3.2	120	1.9	1.2	1.7	1.0	1.9
C65	Renal Pelvis	2	0.0	0	0	0.0	0.1	4	0.1	0	0.1	0.1	0.1
C66	Ureter	1	0.0	0	0	0.0	0.1	1	0	0	0	0.0	0.0
C67	Bladder	227	4.3	2.2	3.8	1.8	4.3	53	0.8	0.5	0.9	0.3	1.1
C68	Other Urinary organs	1	0.0	0	0	0.0	0.0	2	0	0	0	0.0	0.0
C69	Eye	23	0.4	0.2	0.3	0.1	0.3	22	0.3	0.2	0.3	0.1	0.2
C70-C72	Brain, Nervous system	180	3.4	1.8	2.1	1.5	1.9	128	2	1.3	1.5	1.0	1.4
C73	Thyroid	182	3.4	1.8	2.2	1.7	2.4	702	11	7	8.1	6.4	7.8
C74	Adrenal gland	16	0.3	0.2	0.2	0.1	0.2	13	0.2	0.1	0.1	0.1	0.1
C75	Other Endocrine	0	0.0	0	0	0.0	0.0	1	0	0	0	0.0	0.0
C81	Hodgkin disease	239	4.5	2.3	2.5	1.6	2.2	154	2.4	1.5	1.5	1.0	1.4
C82-C85;C96	Non-Hodgkin lymphoma	435	8.2	4.3	6.1	3.3	6.5	311	4.9	3.1	4.6	2.6	5.2
C88	Immunoproliferative dis.	0	0.0	0	0	0.0	0.0	1	0	0	0	0.0	0.0
C90	Multiple Myeloma	64	1.2	0.6	1	0.6	1.2	53	0.8	0.5	0.8	0.5	1.0
C91	Lymphoid Leukaemia	233	4.4	2.3	2.4	1.2	1.8	161	2.5	1.6	1.7	0.9	1.3
C92-C94	Myeloid Leukaemia	144	2.7	1.4	1.7	1.0	1.7	104	1.6	1	1.2	0.8	1.3
C95	Leukaemiaunspec.	25	0.5	0.2	0.3	0.1	0.2	17	0.3	0.2	0.2	0.1	0.1
Other	Other & unspecified	174	3.3	1.7	2.7	1.4	2.9	176	2.8	1.7	2.7	1.4	3.0

### Adult Cancers in Saudi Arabia, 2013 (>14 years)

Between January and December 2013, the total number of adult cancer incidence cases reported was 14,796. Overall cancer was more in females than in males. Cancer affected 6,880 (46.5%) males and 7,916 (53.5%) females with ratio male to female of 86:100. Of all cases, there were 11,233 Saudi, 3,341 of Non-Saudis and 222 of unknown nationalities. As shown on table 2.7.1, the total number of analyzed cases were 14,161.

**Table 2.7.1 Distribution of Reported Adult Cancer Cases in Saudi Arabia by Nationality and Sex, 2013**

Saudis						Unknown Nationality*	Non-Saudis							
Analyzed			Non-analyzed*				Analyzed			Non-analyzed*				
Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
4874	6053	10927	138	168	306	112	110	222	1697	1537	3234	59	48	107

**Table 2.7.2 Most Common Cancers among Saudi Adults, 2013**

Sites	No.	%
Breast	1873	17.1
Colorectal	1383	12.7
Thyroid	874	8.0
NHL	699	6.4
Liver	486	4.4
Lung	432	4.0
Leukemia	406	3.7
Hodgkin disease	338	3.1
Stomach	316	2.9
Prostate	305	2.8

**Table 2.7.3 Most Common Cancers among Saudi Adults by Sex, 2013**

Male	4874	%	Female	6053	%
Colorectal	735	13.1	Breast	1852	30.6
NHL	398	8.2	Thyroid	693	11.4
Liver	333	6.8	Colorectal	648	10.7
Lung	323	6.6	NHL	301	5.0
Prostate	305	6.3	Corpus Uteri	289	4.8
Leukemia	250	4.9	Ovary	189	3.1
Bladder	223	4.6	Leukemia	156	2.6
Hodgkin disease	200	4.1	Liver	153	2.5
Stomach	195	4.0	Hodgkin disease	138	2.3
Thyroid	181	3.7	Stomach	121	2.0

\*\*unknown nationalities, in situ cases and ICD-10 conversion failure are excluded from analysis.

### Childhood Cancers in Saudi Arabia, 2013 (≤ 14 years)

The total incident cases reported among children (0 - 14 years) between January and December 2013 were 854. This represents 5.5% of the total number of cancers in Saudi Arabia. The reported incidents show that cancer was more common among boys than girls, 479 (56.1%) cases were reported among boys and 375 (44.0%) among girls. The reported cancer cases were 722 Saudis, 123 non-Saudi and 9 of "unknown nationality". Based on Table 2.8.1, the total numbers of analyzed cases were 838 including 716 (85.4%) Saudi and 122 (14.6%) Non-Saudi. Among Saudi, 407 (56.8%) were boys and 309 (43.2%) were girls. The boys to girls ratio among Saudis was 131:100.

Childhood cancers accounted for 6.1% of all cancer among Saudis. The leading cancer among Saudi children was Leukemia, which accounted for 38.8 %, followed by Brain 13.5% then Hodgkin Disease 7.7% and NHL 6.6% (Table 2.8.2). The table 2.8.3 shows the top ten sites by sex and frequency, and Table 2.8.4 shows the number and proportion of the morphological types for the most common types of cancer.

**Table 2.8.1 Most Common Cancers among Saudi Adults, 2013**

Saudis			Unknown Nationality*			Non-Saudis								
Analyzed		Non-analyzed*				Analyzed		Non-analyzed*						
Boys	Girls	Total	Boys	Girls	Total	Boys	Girls	Total						
407	309	716	2	4	6	7	2	9	62	60	122	1	0	1

**Table 2.8.2 Most Common Cancer among Saudi Children, 2013**

Sites	No.	%
Leukemia	278	38.8
Brain, CNS	97	13.5
Hodgkin disease	55	7.7
NHL	47	6.6
Kidney	44	6.1
Bone	41	5.7
Connective, Soft tissue	29	4.1
Eye	25	3.5
Adrenal gland	21	2.9
Thyroid	10	1.4

**Table 2.8.3 Most Common Cancer among Saudi Children by sex, 2013**

Boys	255	%	Girls	309	%
Leukemia	152	59.6	Leukemia	126	40.8
Brain CNS	59	23.1	Brain, CNS	38	12.3
Hodgkin disease	39	15.3	Kidney	20	6.5
NHL	37	14.5	Bone	18	5.8
Kidney	24	9.4	Connective, Soft tissue	16	5.2
Bone	23	9.0	Hodgkin disease	16	5.2
Connective, Soft tissue	13	5.1	Eye	13	4.2
Eye	12	4.7	Adrenal gland	11	3.6
Adrenal gland	10	3.9	NHL	10	3.2
Liver	6	2.4	Thyroid	9	2.9

**Table 2.8.4 Number and Percentage of Morphological Types for the Most Common types of Cancer among Saudi Children, 2013**


Primary Site	Code	Morphology	Male	%	Female	%
Leukemia	9863	Precursor B-cell lymphoblastic leukemia	79	52	79	63
	9835	Precursor cell lymphoblastic leukemia, NOS	20	13	17	13
	9837	Precursor T-cell lymphoblastic leukemia	16	11	5	4
	9861	Acute myeloid leukemia, NOS	10	7	8	6
	9826	Burkitt cell leukemia	6	4	2	2
	9801	Acute leukemia, NOS	4	3	3	2
	9891	Acute monocytic leukemia	3	2	1	1
	9896	Acute myeloid leukemia, t(8;21)(q22;q22)	2	1	0	0
	9867	Acute myelomonocytic leukemia	2	1	0	0
	9946	Juvenile myelomonocytic leukemia	2	1	3	2
	9805	Acute biphenotypic leukemia	1	1	0	0
	Others	7	5	8	6	
	Total	152	100	126	100	
Brain	9470	Medulloblastoma, NOS	21	35.6	17	44.7
	9380	Glioma, malignant	9	15.3	6	15.8
	9400	Astrocytoma, NOS	3	5.1	1	2.6
	9508	Atypical teratoid/rhabdoid tumor	3	5.1	1	2.6
	9471	Desmoplastic nodular medulloblastoma	3	5.1	1	2.6
	9392	Ependymoma, anaplastic	3	5.1	5	13.2
	9440	Glioblastoma, NOS	3	5.1	2	5.3
	9390	Choroid plexus carcinoma	2	3.4	0	0.0
	9391	Ependymoma, NOS	2	3.4	0	0.0
	8000	Neoplasm, malignant	2	3.4	0	0.0
	Others	8	13.6	5	13.2	
	Total	59	100.0	38	100.0	
Hodgkin lymphoma	9663	Hodgkin lymphoma, nodular sclerosis, NOS	14	35.9	11	68.8
	9652	Hodgkin lymphoma, mixed cellularity, NOS	10	25.6	4	25.0
	9650	Hodgkin lymphoma, NOS	7	17.9	1	6.3
	9659	Hodgkin lymphoma, nodular lymphocyte predominance	4	10.3	0	0.0
	9665	Hodgkin lymphoma, nodular sclerosis, grade 1	2	5.1	0	0.0
	9653	Hodgkin lymphoma, lymphocyte depletion, NOS	1	2.6	0	0.0
	9651	Hodgkin lymphoma, lymphocyte-rich	1	2.6	0	0.0
	Total	39	100.0	16	100.0	
NHL	96873	Burkitt lymphoma, NOS	15	41	3	30.0
	97003	Mycosis fungoides	4	11	2	20.0
	96803	Malignant lymphoma, large B-cell, diffuse, NOS	4	11	0	0.0
	97543	Langerhans cell histiocytosis, disseminated	3	8	1	10.0
	97273	Precursor cell lymphoblastic lymphoma, NOS	3	8	0	0.0
	97293	Precursor T-cell lymphoblastic lymphoma	2	5	1	10.0
	95903	Malignant lymphoma, NOS	2	5	0	0.0
		Others	4	11	3	30.0
	Total	37	100	10	100.0	
Kidney	8960	Nephroblastoma, NOS	22.0	91.7	18.0	90.0
	8963	Malignant rhabdoid tumor	2.0	8.3	0.0	0.0
	8959	Malignant cystic nephroma	0.0	0.0	1.0	5.0
	9364	Peripheral neuroectodermal tumor	0.0	0.0	1.0	5.0
		Total	24	100.0	20	100.0

Table 2.8.4 Continued ...


Primary Site	Code	Morphology	Male	%	Female	%
Bone	9260	Ewing sarcoma	16	69.6	5	27.8
	9180	Osteosarcoma, NOS	3	13.0	7	38.9
	8910	Embryonal rhabdomyosarcoma, NOS	1	4.3	0	0.0
	9364	Peripheral neuroectodermal tumor	1	4.3	2	11.1
	9473	Primitive neuroectodermal tumor, NOS	1	4.3	0	0.0
	9183	Telangiectatic osteosarcoma	1	4.3	0	0.0
	9181	Chondroblastic osteosarcoma	0	0.0	3	16.7
	9041	Synovial sarcoma, spindle cell	0	0.0	1	5.6
		Total	23	100.0	18	100.0
Connective Tissue	8910	Embryonal rhabdomyosarcoma, NOS	3	23	1	6
	9364	Peripheral neuroectodermal tumor	2	15	0	0
	8900	Rhabdomyosarcoma, NOS	2	15	3	19
	9071	Yolk sac tumor	2	15	1	6
	8810	Fibrosarcoma, NOS	1	8	0	0
	8814	Infantile fibrosarcoma	1	8	0	0
		Others	2	15	11	69
		Total	13	100	16	100
Eye	9511	Retinoblastoma, differentiated	5	41.7	5	38.5
	9510	Retinoblastoma, NOS	4	33.3	4	30.8
	9512	Retinoblastoma, undifferentiated	3	25.0	2	15.4
	8910	Embryonal rhabdomyosarcoma, NOS	0	0.0	1	7.7
	9513	Retinoblastoma, diffuse	0	0.0	1	7.7
		Total	12	100.0	13	100.0
Adrenal gland	9490	Ganglioneuroblastoma	0	0.0	1	9.1
	9500	Neuroblastoma, NOS	10	100.0	10	90.9
		Total	10	100.0	11	100.0
Thyroid	8260	Papillary adenocarcinoma, NOS	1	100.0	7	77.8
	8340	Papillary carcinoma, follicular variant	0	0.0	2	22.2
		Total	1	100.0	9	100.0

## International Comparison of Age-Standardized Incidence Rates for all Types and Cancer by sex

**2.6.1 Comparison of ASR\* for Saudi Males with Selected Countries\*\***



**2.6.2 Comparison of ASR\* for Saudi Female with Selected Countries\***



\*ASR per 100,000

\*\* Source for this information is summarized on page 55



**PART III**  
**CANCERS INCIDENCE**  
**FOR MOST COMMON SITES 2013**

### Cancers Incidence for Most Common Sites, 2013

In this section, the incidence of the most common cancers among Saudi males and females are outlined in accordance to their relative frequencies. The relevant data incorporate details for all patients presented over the period of January through December 2013.


**Table 3.1 Most Common Cancer among Saudis by Sex, 2013**

Sites	Male	Female	All	%
Breast	21	1853	1874	16.1
Colorectal	736	651	1387	11.9
Thyroid	182	702	884	7.6
NHL	435	311	746	6.4
Leukemia	402	282	684	5.9
Liver	339	156	495	4.3
Lung	326	109	435	3.7
Hodgkin disease	239	154	393	3.4
Stomach	195	121	316	2.7
Kidney	193	120	313	2.7

### Female Breast (C50)

There were 1,853 female breast cancer cases for year 2013. Breast cancer ranked the 1st among females accounting for 29.1% of all newly diagnosed female cancers (6364) in year 2013. The ASR was 25.5/ 100,000 for female population. The median age at diagnosis was 50 years (Ranged between 20 and 116 years).


**Figure 3.1.1 Age-Specific Incidence Rate (AIR) for Female Breast Cancer in Saudi Arabia, 2013**




**Table 3.1.1 Morphological Distribution of Female Breast Cancer in Saudi Arabia, 2013**

ICD O-3	Morphology	No.	%
8500	Infiltrating duct carcinoma, NOS	1457	78.6
8520	Lobular carcinoma, NOS	115	6.2
8522	Infiltrating duct and lobular carcinoma	66	3.6
8000	Neoplasm, malignant	42	2.3
8010	Carcinoma, NOS	34	1.8
8523	Infiltrating duct mixed with other types of carcinoma	25	1.3
8510	Medullary carcinoma, NOS	14	0.8
8480	Mucinous adenocarcinoma	14	0.8
9020	Phyllodes tumor, malignant	10	0.5
8504	Intracystic carcinoma, NOS	9	0.5
	Others	67	3.6

**Figure 3.1.2 Stage Distribution of Female Breast Cancer in Saudi Arabia, 2013**



**Figure 3.1.4 Comparison of ASR\* for Female Breast Cancer among Saudi with ASR in Selected countries\*\***




\*ASR per 100,000

\*\* Source for this information is summarized on page 55

### Colorectal (C18-C20)

There were 1,387 cases of colorectal cancer accounting for 11.9% of all newly diagnosed cases in year 2013. This cancer ranked the 1<sup>st</sup> among male and the 3<sup>rd</sup> among female. It affected 736 (53.1%) males and 651 (46.9 %) females with a male to female ratio of 113:100. The ASR males was 11.7/ 100,000 and for females 10.1/ 100,000. The median age at diagnosis was 60 years among males (range between 13 and 98 years) and 56 years among females (range between 12 and 109 years).


**Figure 3.2.1 Age Specific Incidence Rate ( AIR ) for Colorectal Cancer in Saudi Arabia, 2013**




**Table 3.2.1 Morphological Distribution of Colorectal Cancer in Saudi Arabia, 2013**

ICD O-3	Morphology	Male	%	Female	%
8140	Adenocarcinoma, NOS	595	81.0	529	81.3
8480	Mucinous adenocarcinoma	58	7.9	44	6.8
8000	Neoplasm, malignant	12	1.6	11	1.7
8260	Adenocarcinoma in tubulovillous adenoma	11	1.5	16	2.5
8490	Signet ring cell carcinoma	11	1.5	11	1.7
8010	Carcinoma, NOS	8	1.1	6	0.9
8210	Adenocarcinoma in adenomatous polyp	7	1.0	4	0.6
8261	Adenocarcinoma in villous adenoma	7	1.0	8	1.2
8144	Adenocarcinoma, intestinal type	5	0.7	2	0.3
8246	Neuroendocrine carcinoma, NOS	5	0.7	3	0.5
	Others	17	2.2	17	2.6

**Figure 3.2.2 Stage Distribution of Colorectal Cancer in Saudi Arabia, 2013**



**\*\*Figure 3.2.4 Comparison of ASR\* for Colorectal Cancer among Saudi with ASR in Selected countries\*\***




\*ASR per 100,000

\*\*Source for this information is summarized on page 55

## Thyroid (C73)

There were 884 cases of thyroid cancer accounting for 7.6% of all newly diagnosed cases for the year 2013. This cancer ranked 2nd among female and 12th among male population. It affected 702 (79.4%) females and 182 (20.4%) males, with a female to male ratio of 385:100. The ASR was 8.1/ 100,000 for females and 2.2 / 100,000 for male. The median age at diagnosis was 40 years among females (range between 2 and 90years) and 41 years among males (range between 12 and 85 years).

**Figure 3.3.1 Age-Specific Incidence Rate (AIR) for Thyroid Cancer in Saudi Arabia, 2013**



**Table 3.3.1 Morphological Distribution of Thyroid Cancer in Saudi Arabia, 2013**

ICD O-3	Morphology	Male	%	Female	%
8260	Papillary adenocarcinoma, NOS	107	58.8	380	54.2
8340	Papillary carcinoma, follicular variant	19	10.4	98	14.0
8341	Papillary microcarcinoma	18	9.9	88	12.6
8343	Papillary carcinoma, encapsulated	6	3.3	26	3.7
8335	Follicular carcinoma, minimally invasive	3	1.6	17	2.4
8344	Papillary carcinoma, columnar cell	6	3.3	17	2.4
8050	Papillary carcinoma, NOS	1	0.5	17	2.4
8330	Follicular adenocarcinoma, NOS	2	1.1	16	2.3
8510	Medullary carcinoma, NOS	6	3.3	8	1.1
8021	Carcinoma, anaplastic, NOS	3	1.6	6	0.9
	Others	11	6.0	28	4.0

**Figure 3.3.2 Stage Distribution of Thyroid Cancer in Saudi Arabia, 2013**





Figure 3.3.4 Comparison of ASR\* for Thyroid Cancer among Saudi with ASR in Selected countries\*\*




\*ASR per 100,000

\*\* Source for this information is summarized on page 55

### Non-Hodgkin Lymphoma (C82-C85; C96)

There were 746 cases of Non-Hodgkin Lymphoma accounting for 6.4% of all newly diagnosed cancers in year 2013. This cancer ranked 2nd male population and 4th among female population. It affected 435 (58.3%) males and 311 (41.7%) females with a male to female ratio of 139:100. The ASR for males was 6.1/ 100,000 and 4.6/ 100,000 for females. The median age at diagnosis was 53 years among males(range between 0 and 105 years) and 56 years among females (range between 0 and 105 years).


**Figure 3.4.1 Age-Specific Incidence Rate (AIR) for NHL in Saudi Arabia, 2013**




**Table 3.4.1 Morphological Distribution of NHL in Saudi Arabia, 2013**

ICD O-3	Morphology	Male	%	Female	%
9680	Malignant lymphoma, large B-cell, diffuse, NOS	183	42	169	54
9687	Burkitt lymphoma, NOS	36	8	13	4
9591	Malignant lymphoma, non-Hodgkin, NOS	26	6	23	7
9590	Malignant lymphoma, NOS	25	6	12	4
9702	Mature T-cell lymphoma, NOS	20	5	7	2
9714	Anaplastic large cell lymphoma, T cell and Null cell type	17	4	6	2
9690	Follicular lymphoma, NOS	14	3	10	3
9699	Marginal zone B-cell lymphoma, NOS	14	3	7	2
9700	Mycosis fungoides	14	3	18	6
9698	Follicular lymphoma, grade 2	13	3	13	4
	Others	73	17	33	11

**Figure 3.4.2 Stage Distribution of NHL in Saudi Arabia, 2013**



**Figure 3.4.4 Comparison of ASR\* for NHL among Saudi with ASR in Selected Countries\*\***



\*ASR per 100,000


\*\* Source for this information is summarized on page 55

### Leukemia (C91-C95)

There were 684 cases of leukemia accounting for 5.9 % of all newly diagnosed cancers in year 2013. This cancer ranked 3rd for males and the 6th for females. It affected 402 (58.8%) males and 282 (41.2%) females with a male to female ratio of 142:100. The ASR in males was 4.4/ 100,000 and 3.1/ 100,000 for females.


The median age at diagnosis is 21 years among males (between range 0 and 96 years) and 18 years among females (range between 0 and 97 years).

Figure 3.5.1 Age-Specific Incidence Rate (AIR) for Leukemia in Saudi Arabia, 2013



ICD O-3	Morphology	Male	%	Female	%
9836	Precursor B-cell lymphoblastic leukemia	119	29.6	99	35.1
9861	Acute myeloid leukemia, NOS	46	11.4	36	12.8
9863	Chronic myeloid leukemia, NOS	39	9.7	21	7.4
9823	B-cell chronic lymphocytic leukemia/small lymphocytic lymphom	35	8.7	23	8.2
9835	Precursor cell lymphoblastic leukemia, NOS	31	7.7	26	9.2
9837	Precursor T-cell lymphoblastic leukemia	27	6.7	8	2.8
9800	Leukemia, NOS	14	3.5	7	2.5
9866	Acute promyelocytic leukemia, t(15;17)(q22;q11-12)	12	3.0	14	5.0
9826	Burkitt cell leukemia	11	2.7	2	0.7
9875	Chronic myelogenous leukemia, BCR/ABL positive	9	2.2	4	1.4
	Others	59	13.9	42	14.9

Figure 3.5.3 ASR\* Regional Distribution of Leukemia in Saudi Arabia with ASR in Selected Countries\*\*




\* ASR per 100,000

\*\* Source for this information is summarized on page 55

## Liver (C22)

There were 495 cases of liver cancer accounting for 4.3% of all newly diagnosed cases in year 2013. This cancer ranked 4th in males and 8th in females. It affected 339 (68.5%) males and 159 (32.1%) females with a male to female ratio of 213:100. The ASR was 5.9/ 100,000 for males and 2.6/ 100,000 for females. The median age at diagnosis was 67 years in males (range between 0 and 111 years) and 65 years in females (range between 2 and 93 years).


**Figure 3.6.1 Age-Specific Incidence Rate (AIR) for Liver Cancer in Saudi Arabia, 2013**




**Table 3.6.1 Morphological Distribution of Liver Cancer in Saudi Arabia, 2013**

ICD O-3	Morphology	Male	%	Female	%
8170	Hepatocellular carcinoma, NOS	267	78.8	105	67.3
8160	Cholangiocarcinoma	16	4.7	19	12.2
8000	Neoplasm, malignant	15	4.4	10	6.4
8140	Adenocarcinoma, NOS	14	4.1	14	9.0
8010	Carcinoma, NOS	6	1.8	0	0.0
8970	Hepatoblastoma	6	1.8	0	0.0
8180	Combined hepatocellular carcinoma and cholangiocarcinoma	4	1.2	1	0.6
9120	Hemangiosarcoma	2	0.6	0	0.0
8174	Hepatocellular carcinoma, clear cell type	2	0.6	1	0.6
8162	Klatskin tumor	2	0.6	0	0.0
	Others	5	1.5	6	3.8

**Figure 3.6.2 Stage Distribution of Liver Cancer in Saudi Arabia, 2013**



**Figure 3.6.4 Comparison of ASR\* for Liver Cancer among Saudis with ASR in Selected Countries\*\***




\* ASR per 100,000

\*\* Source for this information is summarized on page 55

### Lung (C33-C34)

There were 435 cases of lung cancer accounting for 3.7% of all diagnosed cases in year 2013. Lung cancer ranked 5<sup>th</sup> among male and 15<sup>th</sup> among female. It affected 326 (74.9%) males and 109 (25.1%) females with a male to female ratio of 299:100. The ASR was 5.5/ 100,000 for males and 1.8/ 100,000 for females. The median age at diagnosis was 66 years among males (range between 3 and 91 years) and 74 years among females (range between 17 and 91 years).


**Figure 3.7.1 Age-Specific Incidence Rate (AIR) for Lung Cancer in Saudi Arabia, 2013**




**Table 3.7.1 Morphological Distribution of Lung Cancer in Saudi Arabia, 2013**

ICD O-3	Morphology	Male	%	Female	%
8140	Adenocarcinoma, NOS	120	36.8	43	39.4
8070	Squamous cell carcinoma, NOS	64	19.6	15	13.8
8041	Small cell carcinoma, NOS	37	11.3	4	3.7
8046	Non-small cell carcinoma	28	8.6	11	10.1
8000	Neoplasm, malignant	15	4.6	12	11.0
8010	Carcinoma, NOS	8	2.5	4	3.7
8480	Mucinous adenocarcinoma	8	2.5	1	0.9
8246	Neuroendocrine carcinoma, NOS	6	1.8	2	1.8
8033	Pseudosarcomatous carcinoma	5	1.5	0	0.0
8240	Carcinoid tumor, NOS	4	1.2	3	2.8
	Others	31	9.5	14	12.8

**Figure 3.7.2 Stage Distribution of Lung Cancer in Saudi Arabia, 2013**



**Figure 3.7.4 Comparison of ASR\* for Lung Cancer among Saudi with ASR in Selected Countries\*\***



\*ASR per 100,000

\*\* Source for this information is summarized on page 55

### Hodgkin Disease (C81)

There were 393 cases of Hodgkin disease accounting for 3.4% of all newly diagnosed cases in year 2013. Hodgkin disease ranked 7th among male and 9th among female. It affected 239 (60.8%) males and 154 (39.2%) females with a male to female ratio of 155:100. The ASR was 2.5/ 100,000 for males and 1.5/ 100,000 for females. The median age at diagnosis was 26 years (range between 2 and 95 years) in males and 24 years (range between 3 and 77) in females.

Figure 3.8.1 Age-Specific Incidence Rate (AIR) for Hodgkin Disease in Saudi Arabia, 2013






Table 3.8.1 Morphological Distribution of Hodgkin Disease in Saudi Arabia, 2013

ICD O-3	Morphology	Male	%	Female	%
9663	Hodgkin lymphoma, nodular sclerosis, NOS	102	42.7	88	57.1
9652	Hodgkin lymphoma, mixed cellularity, NOS	39	16.3	22	14.3
9650	Hodgkin lymphoma, NOS	36	15.1	18	11.7
9659	Hodgkin lymphoma, nodular lymphocyte predominance	23	9.6	6	3.9
9665	Hodgkin lymphoma, nodular sclerosis, grade 1	16	6.7	7	4.5
9651	Hodgkin lymphoma, lymphocyte-rich	11	4.6	4	2.6
9653	Hodgkin lymphoma, lymphocyte depletion, NOS	7	2.9	3	1.9
9667	Hodgkin lymphoma, nodular sclerosis, grade 2	4	1.7	5	3.2
9662	Hodgkin sarcoma	1	0.4	0	0.0
9664	Hodgkin lymphoma, nodular sclerosis, cellular phase	0	0.0	1	0.6

Figure 3.8.2 Stage Distribution of Hodgkin Disease in Saudi Arabia, 2013



**Figure 3.8.4 Comparison of ASR\* for Hodgkin Disease among Saudi with ASR in Selected Countries\*\***



\*ASR per 100,000

\*\* Source for this information is summarized on page 55

## Stomach (C16)

There were 316 cases of stomach cancer accounting for 2.7% of all newly diagnosed cases in year 2013. Stomach cancer ranked 9th among male and 12th among female. It affected 195 (61.7%) males and 121 (38.3%) females with a male to female ratio of 161:100. The ASR was 3.3/ 100,000 for males and 1.8/ 100,000 for females. The median age at diagnosis was 67 years (range between 21 and 91 years) in males and 58 years (range between 19 and 97) in females.

Figure 3.9.1 Age-Specific Incidence Rate (AIR) for Stomach Cancer in Saudi Arabia, 2013






Table 3.9.1 Morphological Distribution of Stomach Cancer in Saudi Arabia, 2013

ICD O-3	Morphology	Male	%	Female	%
8140	Adenocarcinoma, NOS	82	42.1	46	38.0
8490	Signet ring cell carcinoma	50	25.6	30	24.8
8144	Adenocarcinoma, intestinal type	19	9.7	11	9.1
8936	Gastrointestinal stromal sarcoma	11	5.6	9	7.4
8145	Carcinoma, diffuse type	6	3.1	3	2.5
8010	Carcinoma, NOS	6	3.1	4	3.3
8246	Neuroendocrine carcinoma, NOS	5	2.6	5	4.1
8240	Carcinoid tumor, NOS	4	2.1	2	1.7
8482	Mucinous adenocarcinoma	4	2.1	2	1.7
8000	Neoplasm, malignant	3	1.5	5	4.1
	Others	5	2.6	4	3.3

Figure 3.9.2 Stage Distribution of Stomach Cancer in Saudi Arabia, 2013



**Figure 3.9.4 Comparison of ASR\* for Stomach Cancer among Saudi with ASR in Selected Countries\*\***




\*ASR per 100,000

\*\* Source for this information is summarized on page 55

### Kidney (C64)

There were 313 cases of Kidney cancer accounting for 2.7% of all newly diagnosed cases in year 2013. This cancer ranked 10th among male population and 13th among female population. It affected 193 (61.7%) males and 120 (38.3%) females with a male to female ratio of 160:100. The ASR was 2.9/ 100,000 for male and 1.7/ 100,000 for females. The median age at diagnosis was 56 years among males (range between 0 and 92 years) and 49 years among female (range between 0 and 91 years).

**Figure 3.10.1 Age-Specific Incidence Rate (AIR) for Kidney Cancer in Saudi Arabia, 2013**



**Table 3.10.1 Morphological Distribution of Kindney Cancer in Saudi Arabia, 2013**

ICD O-3	Morphology	Male	%	Female	%
8312	Renal cell carcinoma, NOS	97	50.3	56	46.7
8310	Clear cell adenocarcinoma, NOS	26	13.5	12	10.0
8960	Nephroblastoma, NOS	22	11.4	18	15.0
8260	Papillary adenocarcinoma, NOS	13	6.7	3	2.5
8317	Renal cell carcinoma, chromophobe type	13	6.7	15	12.5
8130	Papillary transitional cell carcinoma	5	2.6	2	1.7
8318	Renal cell carcinoma, sarcomatoid	5	2.6	4	3.3
8120	Transitional cell carcinoma, NOS	4	2.1	0	0.0
8010	Carcinoma, NOS	2	1.0	1	0.8
8963	Malignant rhabdoid tumor	2	1.0	0	0.0
	Others	4	2	9	8

**Figure 3.10.2 Stage Distribution of Kindney Cancer in Saudi Arabia, 2013**





Figure 3.10.4 Comparison of ASR\* for Kidney Cancer among Saudi with ASR in Selected Countries\*\*



\*ASR per 100,000

\*\* Source for this information is summarized on page 55

## References:

- 1- Canadian Cancer Statistics 2015. Available from:  
<https://www.cancer.ca/~media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2015-EN.pdf>
- 2- Cancer in Ireland 2013: Annual Report of the national Cancer Registry. National Cancer Registry Ireland.
- 3- Cancer Incidence and Mortality in Western Australia, 2014. A report of the Western Australian Cancer Registry.
- 4- National Cancer registry, Republic of Korea. Available from:  
<http://www.e-crt.org/upload/pdf/crt-2015060-.pdf>
- 5- Cancer in Norway 2014. Cancer Incidence, mortality, survival and prevalence in Norway. Available from:  
[https://www.kreftregisteret.no/globalassets/cancer-in-norway/2014/cin2014-special\\_issue.pdf](https://www.kreftregisteret.no/globalassets/cancer-in-norway/2014/cin2014-special_issue.pdf)
- 6- Singapore Cancer Registry. Interim Annual Registry Report. Trends in Cancer Incidence in Singapore 2010-2014. National Registry of Diseases Office (NRDO). Available from:  
[https://www.nrdo.gov.sg/docs/librariesprovider3/default-document-library/cancer-trends-report-2010---2014\\_web.pdf?sfvrsn=0](https://www.nrdo.gov.sg/docs/librariesprovider3/default-document-library/cancer-trends-report-2010---2014_web.pdf?sfvrsn=0)
- 7- The Hashemite Kingdom of Jordan Ministry of Health. Non Communicable Diseases Directorate Jordan Cancer Registry Cancer Incidence in Jordan 2012. Available from:  
<http://moh.gov.jo/EN/Pages/Periodic-Newsletters.aspx>
- 8- National Cancer Institute surveillance, Epidemiology and End Results program (NIH). SEER Cancer Statistics Review 1975 -2013 USA. Available from:  
[http://seer.cancer.gov/csr/1975\\_2013/browse\\_csr.php?sectionSEL=2&pageSEL=sect\\_02\\_table.05.html](http://seer.cancer.gov/csr/1975_2013/browse_csr.php?sectionSEL=2&pageSEL=sect_02_table.05.html)
- 9- Cancer Incidence in Five continents Vol. X, IARC Scientific Publication, Lyon , France 2014. Available from:  
[https://www.iarc.fr/en/publications/pdfs-online/epi/sp164/CI5volX\\_Full.pdf](https://www.iarc.fr/en/publications/pdfs-online/epi/sp164/CI5volX_Full.pdf)
- 10- Cancer Incidence in Oman Annual Report, 2012.
- 11- Kuwait Cancer Registry Annual Report, 2012.
- 12- Cancer Incidence & Mortality In the Kingdom Of Bahrain, Statistics and trends 2011.



**PART IV**  
**CANCER AMONG NON-SAUDIS**  
**2013**

### Cancer among Non-Saudi Population 2013

Between January and December 2013, a total of 3,464 cancer cases were reported among the Non-Saudi population. In Situ cases were 97 and 11 cases were ICD-O-3 coded that failed to convert to ICD-10 codes as described in the data management (see page 12). This puts the total number of exclusions from the analysis as 108 cases. As a result, the total number of cases analyzed was 3,356. Out of this 1,759 (52.4%) were males and 1,597 (47.6%) were females. The male to female ratio was 110:100. Taking into consideration the population structure of non-Saudis and the fact that cancer is primarily a disease of the elderly; the pattern of cancer had some significant differences. Those under 15 represented 19.4% of the population, those 60 years and over represented 2.7% and the 15 to 59 age-group represented 77.8% of non-Saudi population. During 2013, approximately 3.6% of all cancers occurred before the age of 15, 22.6% occurred between the ages 15 to 39 years, 58.2% were between the ages 40-64, and 15.6% occurred after the age of 64. The median age at diagnosis was 52 years in males (range between 0 and 101 years) and 48 years in females (range between 0 and 104).

**Table 4.1 Ten Most Common Cancer among Non-Saudi, 2013**

Sites	No.	%
Breast	661	19.7
Colorectal	366	10.9
Thyroid	184	5.5
NHL	179	5.3
Lung	130	3.9
Bladder	109	3.2
Prostate	108	3.2
Brain, CNS	101	3.0
Stomach	98	2.9
Kidney	91	2.7


**Table 4.2 Distribution of Cancer Cases among Different Nationalities in Saudi Arabia, 2013**

<b>Nationality</b>	<b>Male</b>	<b>%</b>	<b>Female</b>	<b>%</b>	<b>Total</b>	<b>%</b>
Yemen	307	17.5	256	16.1	563	16.8
Egypt	243	13.8	166	10.4	409	12.2
Philippines	139	7.9	178	11.2	317	9.5
Sudan	174	9.9	133	8.3	307	9.2
Syrian Arab Republic	150	8.5	153	9.6	303	9.0
Pakistan	101	5.7	88	5.5	189	5.6
India	100	5.7	51	3.2	151	4.5
Gaza Strip (Palestine)	40	2.3	68	4.3	108	3.2
Jordan	59	3.4	45	2.8	104	3.1
Bangladesh	60	3.4	10	0.6	70	2.1
Indonesia	14	0.8	53	3.3	67	2.0
Eritrea	18	1.0	41	2.6	59	1.8
Ethiopia	15	0.9	42	2.6	57	1.7
Non-Saudi, NOS	29	1.6	27	1.7	56	1.7
United States of America	38	2.2	10	0.6	48	1.4
United Kingdom	29	1.6	12	0.8	41	1.2
Somalia	20	1.1	20	1.3	40	1.2
Lebanon	21	1.2	13	0.8	34	1.0
Morocco	13	0.7	18	1.1	31	0.9
Afghanistan	16	0.9	14	0.9	30	0.9
Bahrain	10	0.6	19	1.2	29	0.9
Myanmar	11	0.6	17	1.1	28	0.8
Nigeria	9	0.5	19	1.2	28	0.8
Kuwait	12	0.7	12	0.8	24	0.7
Sri Lanka	16	0.9	8	0.5	24	0.7
Other Nationalities	115	6.5	122	7.6	237	7.1
<b>Total</b>	<b>1759</b>	<b>100.0</b>	<b>1595</b>	<b>100.0</b>	<b>3354</b>	<b>100.0</b>

**Table 4.3 Ten Most Common Cancer among Non-Saudi by Sex, 2013**

Male	1759	%	Female	1597	%
Colorectal	249	14.2%	Breast	646	40.5%
NHL	120	6.8%	Thyroid	118	7.4%
Prostate	108	6.1%	Colorectal	117	7.3%
Lung	106	6.0%	Cervix Uteri	60	3.8%
Bladder	99	5.6%	NHL	59	3.7%
Leukemia	92	5.2%	Ovary	57	3.6%
Brain, CNS	69	3.9%	Leukemia	56	3.5%
Stomach	68	3.9%	Corpus Uteri	48	3.0%
Thyroid	66	3.8%	Brain, CNS	32	2.0%
Kidney	65	3.7%	Stomach	30	1.9%
Other Sites	717	41.0%	Other Sites	374	23.5%

**Figure 4.1 Age-Specific Incidence Rate (AIR) for All Cancers among Non-Saudis in Saudi Arabia, 2013**



**PART V**  
**INCIDENCE TABLES**

Table 5.1.1 - Number of Cancer Cases Among Saudi Males by Primary Site and Age Groups, 2013

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	Lip	8	0	0	0	0	0	0	0	1	2	0	0	0	2	0	0	0	3	0.20%
C01-C02	Tongue	49	0	0	0	0	0	2	0	1	2	2	5	2	4	5	3	9	14	0.90%
C03-C06	Mouth	45	0	0	1	1	1	0	0	1	1	3	3	4	4	4	7	6	10	0.90%
C07-C08	Salivary Glands	23	0	0	0	1	1	1	2	3	2	1	0	4	1	1	0	2	3	0.40%
C09	Tonsil	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0.10%
C10	Other Oropharynx	3	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0.10%
C11	Nasopharynx	136	0	0	2	3	3	3	3	12	10	20	18	24	11	9	7	8	5	2.60%
C12-C13	Hypopharynx	10	0	0	0	0	0	0	0	0	1	1	1	1	1	3	0	0	2	0.20%
C14	Pharynx Unspecified	5	0	0	1	1	1	0	0	0	0	0	0	1	0	0	0	0	1	0.10%
C15	Oesophagus	66	0	0	0	0	0	0	0	0	0	2	4	3	7	6	9	5	30	1.20%
C16	Stomach	195	0	0	0	0	0	2	1	6	4	7	13	12	22	21	27	27	53	3.70%
C17	Small Intestine	45	0	0	0	1	1	0	0	3	1	7	1	6	5	2	5	5	8	0.90%
C18	Colon	444	0	0	1	2	3	3	5	17	14	30	42	41	70	59	37	53	72	8.40%
C19-C20	Rectum	292	0	0	0	0	0	5	4	12	6	13	21	35	44	39	32	34	47	5.50%
C21	Anus	17	0	0	0	0	0	0	0	2	0	1	1	2	5	2	1	1	1	0.30%
C22	Liver	339	0	6	0	0	1	0	0	3	0	2	14	30	44	35	62	57	85	6.40%
C23-C24	Gallbladder etc.	77	0	0	0	0	0	0	0	1	1	4	5	6	12	11	14	6	17	1.50%
C25	Pancreas	130	0	0	0	0	0	0	0	0	2	5	7	8	17	16	22	17	36	2.50%
C30-C31	Nose, Sinuses etc.	6	0	0	0	0	0	1	0	0	0	0	0	0	1	1	0	1	1	0.10%
C32	Larynx	78	0	0	0	0	0	0	2	0	0	3	6	9	6	13	7	11	19	1.50%
C33-C34	Trachea, Bronchus, Lung	326	0	1	2	1	1	4	3	4	5	18	16	33	35	30	52	47	75	6.20%
C37-C38	Other Thoracic Organs	21	0	0	0	0	0	4	3	1	3	2	1	1	3	0	0	1	2	0.40%
C40-C41	Bone	63	0	1	9	13	13	6	2	1	3	2	3	4	0	0	1	2	3	1.20%
C43	Melanoma of Skin	13	0	0	0	0	0	0	0	0	1	0	0	0	2	1	4	1	4	0.20%
C44	Other Skin	206	0	0	2	0	0	2	4	4	9	14	7	13	16	15	18	26	76	3.90%
C45	Mesothelioma	7	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	2	3	0.10%
C46	Kaposi Sarcoma	24	0	0	0	0	0	2	0	0	0	1	1	2	2	1	2	2	11	0.50%
C47-C49	Connective, Soft Tissue	85	0	11	0	2	5	4	3	13	5	3	2	8	6	2	5	3	13	1.60%
C50	Breast	21	0	0	0	0	0	0	0	1	1	4	3	3	2	1	2	3	1	0.40%
C60	Penis	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.00%
C61	Prostate	306	0	1	0	0	0	1	0	0	0	1	1	14	24	43	50	46	125	5.80%
C62	Testis	94	0	4	0	0	6	16	25	14	13	7	3	4	0	1	1	0	0	1.80%
C63	Other Male Genital	3	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	1	0	0.10%
C64	Kidney	193	0	21	3	0	1	0	8	2	11	11	18	20	11	19	22	17	29	3.70%
C65	Renal Pelvis	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C66	Ureter	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0.00%
C67	Bladder	227	0	2	1	1	0	1	0	5	3	6	17	19	22	34	30	27	59	4.30%
C68	Other Urinary Organs	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.00%
C69	Eye	23	0	12	0	0	0	0	0	1	0	1	0	1	0	0	2	3	3	0.40%
C70-C72	Brain, Nervous System	180	0	33	14	12	6	9	12	7	6	12	10	16	14	12	5	5	7	3.40%
C73	Thyroid	182	0	0	0	1	2	9	21	27	20	18	15	14	16	14	3	11	11	3.40%
C74	Adrenal Gland	16	0	10	0	0	1	0	0	0	1	0	0	0	1	0	1	1	1	0.30%
C75	Other Endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C81	Hodgkin Disease	239	0	3	13	23	41	31	38	19	11	10	8	10	10	5	4	9	4	4.50%
C82-C85/C96	Non-Hodgkin Lymphoma	435	0	13	17	7	16	25	20	21	25	20	32	35	35	33	39	35	62	8.20%
C88	Immunoproliferative Disease	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C90	Multiple Myeloma	64	0	0	0	0	0	1	1	3	2	4	5	5	10	8	12	4	9	1.20%
C91	Lymphoid Leukemia	233	0	54	50	19	25	15	7	5	4	4	5	5	8	3	9	6	14	4.40%
C92-C94	Myeloid Leukemia	144	0	11	5	7	9	8	15	12	11	9	10	7	12	5	10	5	8	2.70%
C95	Leukemia Unspecified	25	0	4	0	2	2	1	0	3	2	1	1	0	2	0	0	1	6	0.50%
Other	Other & Unspecified	174	0	6	1	0	2	5	5	0	7	6	9	24	19	17	15	18	40	3.30%
All	All Sites Total	5281	0	193	117	97	138	162	187	205	191	255	309	427	509	473	526	519	973	100.00%
Not C44	All Sites but C44	5075	0	193	117	95	138	160	183	201	182	241	302	414	493	458	508	493	897	96.10%

Table 5.1.2 - Number of Cancer Cases Among Saudi Females by Primary Site and Age Groups, 2013

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	Lip	7	0	0	0	0	0	0	0	0	0	1	0	0	0	0	3	1	2	0.10%
C01-C02	Lip	46	0	0	0	0	0	1	0	2	0	3	2	8	7	3	4	6	10	0.70%
C03-C06	Mouth	51	0	0	0	0	0	0	0	0	1	2	6	4	7	6	7	7	9	0.80%
C07-C08	Salivary Glands	15	0	0	0	0	0	0	0	2	1	0	0	2	0	1	2	2	2	0.20%
C09	Tonsil	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.00%
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C11	Nasopharynx	47	0	1	0	1	6	3	4	1	2	0	8	12	2	4	1	2	1	0.70%
C12-C13	Hypopharynx	16	0	0	0	0	0	1	1	0	3	2	2	3	1	0	3	2	0	0.30%
C14	Pharynx Unspecified	3	0	0	0	0	0	0	0	1	1	1	0	0	0	0	0	0	0	0.00%
C15	Oesophagus	49	1	0	0	0	0	0	1	1	2	1	3	2	6	2	7	12	11	0.80%
C16	Stomach	121	0	0	0	0	1	2	4	6	9	6	10	15	11	12	12	8	25	1.90%
C17	Small Intestine	16	0	0	0	0	0	1	0	2	0	0	3	1	2	1	2	2	2	0.30%
C18	Colon	411	0	0	0	3	0	3	13	11	19	32	42	62	52	54	48	29	43	6.50%
C19-C20	Rectum	240	0	0	0	0	0	0	8	9	12	13	28	31	39	21	20	33	26	3.80%
C21	Anus	7	0	0	0	0	0	0	0	0	0	1	4	0	0	0	1	0	0	0.10%
C22	Liver	156	0	1	2	0	0	3	1	2	2	2	14	12	20	16	29	22	30	2.50%
C23-C24	Gallbladder etc.	97	0	0	0	0	0	0	0	0	2	2	3	13	12	13	17	12	23	1.50%
C25	Pancreas	103	0	0	1	1	0	1	2	2	4	1	11	8	15	13	12	13	19	1.60%
C30-C31	Nose, Sinuses etc.	7	0	0	1	0	0	0	0	0	0	0	2	0	1	0	0	0	1	0.10%
C32	Larynx	25	0	0	0	0	0	1	1	0	0	2	2	4	3	4	1	3	4	0.40%
C33-C34	Trachea, Bronchus, Lung	109	0	0	0	0	1	1	2	1	3	8	3	11	15	19	17	12	16	1.70%
C37-C38	Other Thoracic Organs	19	0	3	1	1	0	2	0	1	1	1	1	0	3	2	3	0	0	0.30%
C40-C41	Bone	63	0	2	4	12	16	6	3	6	4	3	0	0	2	2	0	1	2	1.00%
C43	Melanoma of Skin	10	0	1	0	0	0	0	0	0	0	1	0	1	0	1	1	3	2	0.20%
C44	Other Skin	117	0	0	1	0	3	1	3	8	0	6	9	8	13	8	9	15	33	1.80%
C45	Mesothelioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.00%
C46	Kaposi Sarcoma	4	0	0	0	1	0	0	1	0	0	1	0	0	0	0	0	0	1	0.10%
C47-C49	Connective, Soft Tissue	65	0	11	0	4	2	3	4	6	5	3	6	4	8	3	3	0	2	1.00%
C50	Breast	1853	1	0	0	0	0	6	46	126	192	238	314	281	248	135	101	78	87	29.10%
C51	Vulva	11	0	0	0	0	0	1	0	3	0	0	3	0	0	0	1	0	3	0.20%
C52	Vagina	5	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	2	0	0.10%
C53	Cervix Uteri	104	0	0	0	0	0	1	0	5	11	12	20	14	11	12	6	7	5	1.60%
C54	Corpus Uteri	289	0	0	0	0	0	2	0	5	7	10	12	42	59	58	44	23	27	4.50%
C55	Uterus Unspecified	54	0	0	0	0	0	1	0	1	1	5	8	8	7	7	9	3	4	0.80%
C56	Ovary	194	0	0	0	5	2	6	11	12	12	14	20	26	29	14	14	9	20	3.00%
C57	Other Female Genital	12	0	0	0	0	0	0	0	0	0	0	2	1	1	3	2	3	0	0.20%
C58	Placenta	11	0	0	0	0	0	0	6	0	0	2	1	1	0	0	0	0	0	0.20%
C64	Kidney	120	0	16	3	1	1	1	2	0	7	15	14	15	9	8	14	8	6	1.90%
C65	Renal Pelvis	4	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	1	0.10%
C66	Ureter	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.00%
C67	Bladder	53	0	0	0	1	0	1	2	1	0	0	3	3	7	4	6	10	15	0.80%
C68	Other Urinary Organs	2	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0.00%
C69	Eye	22	0	11	2	0	0	0	0	0	1	0	0	0	0	3	1	0	4	0.30%
C70-C72	Brain, Nervous System	128	0	16	17	5	6	10	9	3	7	6	12	4	12	6	8	3	4	2.00%
C73	Thyroid	702	0	1	1	7	22	52	70	96	94	82	88	52	50	36	18	14	19	11.00%
C74	Adrenal Gland	13	0	10	1	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0.20%
C75	Other Endocrine	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.00%
C81	Hodgkin Disease	154	0	2	6	8	29	32	16	18	8	3	8	3	8	1	5	4	3	2.40%
C82-C85,C96	Non-Hodgkin Lymphoma	311	0	3	4	3	12	8	18	13	14	17	24	32	29	30	30	29	45	4.90%
C88	Immunoproliferative Disease	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.00%
C90	Multiple Myeloma	53	0	0	0	0	0	0	0	3	2	7	6	3	7	5	9	5	6	0.80%
C91	Lymphoid Leukemia	161	0	57	33	14	9	10	5	1	1	2	1	2	4	7	5	4	6	2.50%
C92-C94	Myeloid Leukemia	104	0	9	8	2	5	10	5	8	6	8	6	12	8	4	2	7	4	1.60%
C95	Leukemia Unspecified	17	0	2	1	2	1	2	1	0	2	1	0	0	0	0	1	0	5	0.30%
Other	Other & Unspecified	176	0	5	1	0	1	5	5	7	10	8	16	14	18	16	18	18	34	2.80%
All	All Sites Total	6364	2	149	90	70	118	177	246	364	444	525	718	720	729	537	497	413	565	100.00%
Not.C44	All Sites but C44	6247	2	149	89	70	115	176	243	356	444	519	709	712	716	529	488	398	532	98.20%

Table 5.1.3 - Age-Specific Incidence Rate (AIR), Age-Standardized Incidence Rate (ASR) Among Saudi Males (per 100,000) by Primary Site and Age Groups, 2013

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	8	0	0	0	0	0	0	0	0.1	0.3	0	0	0	0.7	0	0	0	2.4	0.1	0.1
C01-C02	Tongue	49	0	0	0	0	0	0.2	0	0.1	0.3	0.4	1.1	0.5	1.4	2.5	2.1	9.7	11.2	0.5	0.8
C03-C06	Mouth	45	0	0	0.1	0.1	0.1	0	0	0.1	0.1	0.5	0.7	1.1	1.4	2	5	6.5	8	0.4	0.7
C07-C08	Salivary Glands	23	0	0	0.2	0	0.1	0.1	0.2	0.4	0.3	0.2	0	1.1	0.4	0.5	0	2.2	2.4	0.2	0.3
C09	Tonsil	3	0	0	0	0	0	0	0	0	0	0	0	0	0.4	0.5	0.7	0	0	0	0.1
C10	Other Oropharynx	3	0	0	0	0	0	0	0	0	0	0	0.2	0	0.4	0	0.7	0	0	0	0
C11	Nasopharynx	136	0	0	0.1	0.2	0.3	0.3	0.3	1.5	1.5	3.6	3.9	6.6	3.9	4.5	5	8.6	4	1.3	1.8
C12-C13	Hypopharynx	10	0	0	0	0	0	0	0	0	0.1	0.2	0.2	0.3	0.4	1.5	0	0	1.6	0.1	0.2
C14	Pharynx Unspecified	5	0	0	0	0.1	0.1	0	0	0	0.1	0	0	0.3	0	0	0	0	0.8	0	0.1
C15	Oesophagus	66	0	0	0	0	0	0	0	0	0	0.4	0.9	0.8	2.5	3	6.4	5.4	24.1	0.6	1.1
C16	Stomach	195	0	0	0	0	0	0.2	0.1	0.8	0.6	1.3	2.8	3.3	7.9	10.6	19.1	29	42.6	1.9	3.3
C17	Small Intestine	45	0	0	0	0	0.1	0	0.1	0.4	0.1	1.3	0.2	1.6	1.8	1	3.5	5.4	6.4	0.4	0.7
C18	Colon	444	0	0	0	0.1	0	0.3	0.6	2.2	2.1	5.4	9.2	11.3	25	29.7	26.2	57	57.8	4.4	7
C19-C20	Rectum	292	0	0	0	0	0	0.5	0.5	1.5	0.9	2.3	4.6	9.6	15.7	19.6	22.6	36.6	37.7	2.9	4.7
C21	Anus	17	0	0	0	0	0	0	0.1	0.3	0	0.2	0.2	0.5	1.8	1	0.7	1.1	0.8	0.2	0.2
C22	Liver	339	0	0.5	0	0	0	0	0	0.4	0	0.7	1.1	1.6	4.3	5.5	9.9	6.5	13.7	0.8	1.3
C23-C24	Gallbladder etc.	77	0	0	0	0	0	0	0	0.1	0.1	0.4	0.7	1.1	1.6	17.6	43.8	61.3	68.3	3.3	5.9
C25	Pancreas	130	0	0	0	0	0	0	0	0.3	0.9	1.5	2.2	2.2	6.1	8.1	15.6	18.3	28.9	1.3	2.2
C30-C31	Nose, Sinuses etc.	6	0	0	0.1	0	0	0.1	0	0	0	0	0	0	0.4	0.5	0	1.1	0.8	0.1	0.1
C32	Larynx	78	0	0	0	0	0	0.1	0.2	0	0.1	0.5	1.3	2.5	2.1	6.5	5	11.8	15.3	0.8	1.3
C33-C34	Trachea, Bronchus, Lung	326	0	0.1	0	0.2	0.1	0.4	0.3	0.5	0.7	3.2	3.5	9.1	12.5	15.1	36.8	50.5	60.2	3.2	5.5
C37-C38	Other Thoracic Organs	21	0	0	0	0	0	0.4	0.3	0.1	0.4	0.4	0.2	0.3	1.1	0	0	1.1	1.6	0.2	0.2
C40-C41	Bone	63	0	0.1	0.7	1.2	1.2	0.6	0.2	0.1	0.4	0.4	0.7	1.1	0	0	0.7	2.2	2.4	0.6	0.6
C43	Melanoma of Skin	13	0	0	0	0	0	0	0	0	0.1	0	0	0	0.7	0.5	2.8	1.1	3.2	0.1	0.2
C44	Other Skin	206	0	0	0.2	0	0.2	0.5	0.5	0.5	1.3	2.5	1.5	3.6	5.7	7.6	12.7	28	61	2	3.3
C45	Mesothelioma	7	0	0	0	0	0	0	0	0	0	0	0	0	0.5	0.7	2.4	2.4	0.1	0.1	
C46	Kaposi Sarcoma	24	0	0	0	0	0	0.2	0	0	0	0.2	0.2	0.5	0.7	0.5	1.4	2.2	8.8	0.2	0.4
C47-C49	Connective, Soft Tissue	85	0	0.9	0	0.2	0.5	0.4	0.3	1.7	0.7	0.5	0.4	2.2	2.1	1	3.5	3.2	10.4	0.8	1
C50	Breast	21	0	0	0	0	0	0	0	0.1	0.1	0.7	0.7	0.8	0.7	0.5	1.4	3.2	0.8	0.2	0.3
C60	Penis	2	0	0	0	0	0	0	0.1	0	0	0	0	0	0.4	0	0	0	0	0	0
C61	Prostate	306	0	0.1	0	0	0	0.1	0	0	0	0.2	0.2	0.8	8.6	21.7	35.4	49.5	100.4	3	5.5
C62	Testis	94	0	0.3	0	0	0.6	1.6	2.8	1.8	1.9	1.3	0.7	1.1	0	0.5	0.7	1	0	0.9	0.9
C63	Other Male Genital	3	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0.7	1.1	0	0	0.1
C64	Kidney	193	0	1.6	0.2	0	0.1	0	0.9	0.3	1.6	2	3.9	5.5	3.9	9.6	15.6	18.3	23.3	1.9	2.9
C65	Renal Pelvis	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.4	0	0	0	0
C66	Ureter	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.1	0	0	0
C67	Bladder	227	0	0.2	0.1	0.1	0	0.1	0	0.6	0.4	1.1	3.7	5.2	7.9	17.1	21.2	29	47.4	2.2	3.8
C68	Other Urinary Organs	1	0	0	0	0	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0	0
C69	Eye	23	0	0.9	0	0	0	0	0	0.1	0	0.2	0	0.3	0	0	1.4	3.2	2.4	0.2	0.3
C70-C72	Brain, Nervous System	180	0	2.6	1.2	1.1	0.6	0.9	1.4	0.9	0.9	2.2	2.2	4.4	5	6	3.5	5.4	5.6	1.8	2.1
C73	Thyroid	182	0	0	0	0.1	0.2	0.9	2.4	3.5	3	3.2	3.3	3.8	5.7	7.1	2.1	11.8	8.8	1.8	2.2
C74	Adrenal Gland	16	0	0.8	0	0	0.1	0	0	0	0.1	0	0	0	0.4	0	0.7	1.1	0.8	0.2	0.2
C75	Other Endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C81	Hodgkin Disease	239	0	0.2	1.1	2.1	3.9	3.2	4.3	2.4	1.6	1.8	1.7	2.7	3.6	2.5	2.8	9.7	3.2	2.3	2.5
C82-C85; C96	Non-Hodgkin Lymphoma	435	0	1	1.4	0.6	1.5	2.5	2.3	2.7	3.7	3.6	7	9.6	12.5	16.6	27.6	37.6	49.8	4.3	6.1
C88	Immunoproliferative Disease	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	64	0	0	0	0	0	0.1	0.1	0.4	0.3	0.7	1.1	1.4	3.6	4	8.5	4	7.2	0.6	1
C91	Lymphoid Leukemia	233	0	4.2	4.1	1.7	2.4	1.5	0.8	0.6	0.6	0.7	1.1	1.4	2.9	1.5	6.4	6.5	11.2	2.3	2.4
C92-C94	Myeloid Leukemia	144	0	0.9	0.4	0.6	0.9	0.8	1.7	1.5	1.6	1.6	2.2	1.9	4.3	2.5	7.1	5.4	6.4	1.4	1.7
C95	Leukemia Unspecified	25	0	0.3	0	0.2	0.2	0.1	0	0.4	0.3	0.2	0.2	0	0.7	0	0	1.1	4.8	0.2	0.3
Other	Other & Unspecified	174	0	0.5	0.1	0	0.2	0.5	0.6	0	1	1.1	2	6.6	6.8	8.6	10.6	19.4	32.1	1.7	2.7
All	All Sites Total	5281	0	15	10	9	13	16	21	26	29	46	67	117	182	238	372	558	781	51.9	78.5
Not C44	All Sites but C44	5075	0	15	10	9	13	16	21	26	27	43	66	114	176	231	359	530	720	49.9	75.2

Table 5.1.4 - Age-Specific Incidence Rate (ASIR), Age-Standardized Incidence Rate (ASR) Among Saudi Females (per 100,000) by Primary Site and Age Groups, 2013

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	7	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	2.1	1	1.6	0.1	0.1
C01-C02	Tongue	46	0	0	0	0	0	0.1	0	0.3	0	0.5	0.4	2.3	2.6	1.6	2.8	6.1	7.8	0.5	0.7
C03-C06	Mouth	51	0	0.1	0	0	0	0	0.1	0	0.1	0.4	1.3	1.1	2.6	3.1	4.9	7.1	7	0.5	0.8
C07-C08	Salivary Glands	15	0	0	0	0	0	0	0.1	0.3	0.1	0	0.4	0.6	0	0.5	1.4	2	1.6	0.1	0.2
C09	Tonsil	2	0	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0	0	0.8	0	0
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C11	Nasopharynx	47	0	0.1	0	0.1	0.6	0.3	0.4	0	0.3	0	1.8	3.4	0.7	2.1	0.7	2	0.8	0.5	0.6
C12-C13	Hypopharynx	16	0	0	0	0	0	0.1	0.1	0	0	0.5	0.4	0.9	0.4	0	2.1	2	0	0.2	0.2
C14	Pharynx Unspecified	3	0	0	0	0	0	0	0	0.1	0.1	0.2	0	0	0	0	0	0	0	0	0
C15	Oesophagus	49	1	0	0	0	0	0	0.1	0.1	0.3	0.2	0.7	0.6	2.2	1	4.9	12.2	8.6	0.5	0.8
C16	Stomach	121	0	0	0	0	0.1	0.2	0.4	1.3	1.1	2.2	4.3	4.1	6.2	8.5	8.1	19.5	1.2	1.8	1.8
C17	Small Intestine	16	0	0	0	0	0	0.1	0	0.3	0	0	0.7	0.3	0.7	0.5	1.4	2	1.6	0.2	0.2
C18	Colon	411	0	0	0.3	0	0	0.3	1.4	1.4	2.8	5.8	9.3	17.7	19.3	27.9	33.9	29.5	33.6	4.1	6.4
C19-C20	Rectum	240	0	0	0	0	0	0	0.9	1.1	1.8	6.2	6.2	8.9	14.5	10.9	14.1	33.5	20.3	2.4	3.7
C21	Anus	7	0	0	0	0	0	0	0	0	0.2	0.2	0.2	1.1	0	0	0.7	0	0	0.1	0.1
C22	Liver	156	0	0.1	0.2	0	0	0.3	0.1	0.3	0.3	0.4	3.1	3.4	7.4	8.3	20.5	22.3	23.5	1.5	2.6
C23-C24	Gallbladder etc.	97	0	0	0	0	0	0	0	0	0.3	0.4	0.7	3.7	4.5	6.7	12	12.2	18	1	1.7
C25	Pancreas	103	0	0	0.1	0.1	0	0.1	0.2	0.3	0.6	0.2	2.4	2.3	5.6	6.7	8.5	13.2	14.9	1	1.7
C30-C31	Nose, Sinuses etc.	7	0	0	0	0	0	0	0	0.1	0	0.2	0.4	0	0.4	0	0	0	0.8	0.1	0.1
C32	Larynx	25	0	0	0	0	0	0.1	0.1	0	0	0.4	0.4	1.1	1.1	2.1	0.7	3	3.1	0.2	0.4
C33-C34	Trachea, Bronchus, Lung	109	0	0	0	0	0.1	0.1	0.2	0.1	0.4	1.4	0.7	3.1	5.6	9.8	12	12.2	12.5	1.1	1.8
C37-C38	Other Thoracic Organs	19	0	0	0	0	0	0	0	0.1	0.1	0.2	0.2	0	1.1	1	2.1	0	0	0.2	0.3
C40-C41	Bone	63	0	0.2	0.3	1.1	1.5	0.6	0.3	0.8	0.6	0.5	0	0	0.7	1	0	1	1.6	0.6	0.6
C43	Melanoma of Skin	10	0	0.1	0	0	0	0	0	0	0	0.2	0	0.3	0	0.5	0.7	3	1.6	0.1	0.2
C44	Other Skin	117	0	0	0.1	0	0.3	0.1	0.3	1	0	1.1	2	2.3	4.8	4.1	6.4	15.2	25.8	1.2	1.8
C45	Mesothelioma	2	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	1	0	0	0
C46	Kaposi Sarcoma	4	0	0	0	0.1	0	0	0.1	0	0	0.2	0	0	0	0	0	0	0.8	0	0
C47-C49	Connective, Soft Tissue	65	0	0.9	0.1	0.4	0.2	0.3	0.4	0.8	0.7	0.5	1.3	1.1	3	1.6	2.1	0	1.6	0.6	0.8
C50	Breast	1833	1	0	0	0	0	0.6	5.1	15.9	28.3	42.9	69.6	80.4	92.3	69.9	71.3	79.2	68	18.4	25.5
C51	Vulva	11	0	0	0	0	0	0.1	0	0.4	0	0	0.7	0	0	0.7	0	0	2.3	0.1	0.1
C52	Vagina	5	0	0	0	0	0	0	0	0	0	0	0	0.3	0.4	0.5	0	2	0	0	0.1
C53	Cervix Uteri	104	0	0	0	0	0	0.1	0	0.6	1.6	2.2	4.4	4	4.1	6.2	4.2	7.1	3.9	1	1.5
C54	Corpus Uteri	289	0	0	0	0	0	0.2	0	0.6	1	1.8	2.7	12	22	30	31.1	23.4	21.1	2.9	4.9
C55	Uterus Unspecified	54	0	0	0	0	0	0.1	0	0.1	0.1	0.9	1.8	2.3	2.6	3.6	6.4	3	3.1	0.5	0.9
C56	Ovary	194	0	0	0.5	0.2	0.6	1.2	1.5	1.8	2.5	4.4	7.4	10.8	7.2	9.9	9.1	15.6	1.9	2.7	2.7
C57	Other Female Genital	12	0	0	0	0	0	0	0	0	0	0	0.4	0.3	0.4	1.6	1.4	3	0	0.1	0.2
C58	Placenta	11	0	0	0	0	0	0.7	0	0	0.1	0.4	0.2	0.3	0	0	0	0	0	0.1	0.1
C59	Kidney	120	0	1.3	0.3	0.1	0.1	0.1	0.2	0	1	2.7	3.1	4.3	3.3	4.1	9.9	8.1	4.7	1.2	1.7
C65	Renal Pelvis	4	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.7	0	0.8	0	0.1
C66	Ureter	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.8	0	0
C67	Bladder	53	0	0	0.1	0	0	0.1	0.2	0.1	0	0	0.7	0.9	2.6	2.1	4.2	10.2	11.7	0.5	0.9
C68	Other Urinary Organs	2	0	0	0	0	0	0	0	0	0	0	0.2	0.3	0	0	0	0	0	0	0
C69	Eye	22	0	0.9	0.2	0	0	0	0	0	0.1	0	0	0	0	1.6	0.7	0	3.1	0.2	0.3
C70-C72	Brain, Nervous System	128	0	1.3	1.5	0.5	0.6	1	1	0.4	1	1.1	2.7	1.1	4.5	3.1	5.6	3	3.1	1.3	1.5
C73	Thyroid	702	0	0.1	0.1	0.6	2.1	5.2	7.7	12.1	13.9	14.8	19.5	14.9	18.6	18.6	12.7	14.2	14.9	7	8.1
C74	Adrenal Gland	13	0	0.8	0.1	0	0	0	0	0.1	0	0	0	0	0.4	0	0	0	0	0.1	0.1
C75	Other Endocrine	1	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0	0	0
C81	Hodgkin Disease	154	0	0.2	0.5	0.7	2.8	3.2	1.8	2.3	1.2	0.5	1.8	0.9	3	0.5	3.5	4.1	2.3	1.5	1.5
C82-C85/C86	Non-Hodgkin Lymphoma	311	0	0.2	0.3	0.3	1.1	0.8	2	1.6	2.1	3.1	5.3	9.2	10.8	15.5	21.2	29.5	35.2	3.1	4.6
C88	Immunoproliferative Disease	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	53	0	0	0	0	0	0	0	0.4	0.3	1.3	1.3	0.9	2.6	2.6	6.4	5.1	4.7	0.5	0.8
C91	Lymphoid Leukemia	161	0	4.7	2.8	1.3	0.9	1	0.6	0.1	0.1	0.4	0.2	0.6	1.5	3.6	3.5	4.1	4.7	1.6	1.7
C92-C94	Myeloid Leukemia	104	0	0.7	0.7	0.2	0.5	1	0.6	1	0.9	1.4	1.3	3.4	3	2.1	1.4	7.1	3.1	1	1.2
C95	Leukemia Unspecified	177	0	0	0.2	0.1	0.2	0.2	0.1	0	0.3	0.2	0	0	0	0	0.7	0	3.9	0.2	0.2
Other	Other & Unspecified	176	0	0.4	0.1	0	0.1	0.5	0.6	0.9	1.5	1.4	3.5	4	6.7	8.3	12.7	18.3	26.6	1.7	2.7
All	All sites Total	6364	2	12	8	6	11	18	27	46	66	95	159	206	271	278	351	419	442	63.1	89.4
Not C44	All sites but C44	6247	2	12	8	6	11	18	27	45	66	93	157	204	266	274	344	404	416	62	87.6

Table 5.4.1 - Number of Cancer Cases Among Non-Saudi Males by Primary Site and Age Groups, 2013

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.10%
C01-C02	Tongue	26	0	0	0	0	0	0	0	1	2	2	1	3	3	5	1	3	1	1.50%
C03-C06	Mouth	21	0	1	0	0	0	0	1	1	4	0	5	3	1	2	1	1	1	1.20%
C07-C08	Salivary Glands	13	0	0	0	0	0	0	0	0	1	5	2	4	1	0	0	0	0	0.70%
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C10	Other Oropharynx	2	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0.10%
C11	Nasopharynx	40	0	0	0	0	0	5	3	3	3	4	8	5	6	1	2	0	0	2.30%
C12-C13	Hypopharynx	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.10%
C14	Pharynx Unspecified	3	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0.20%
C15	Oesophagus	15	0	0	0	0	0	0	2	1	2	1	2	1	0	2	1	1	2	0.90%
C16	Stomach	68	0	0	0	1	0	0	1	4	4	8	10	10	8	7	8	3	4	3.90%
C17	Small Intestine	19	0	0	0	0	0	0	0	2	0	2	5	3	1	5	0	1	1	1.10%
C18	Colon	156	0	0	0	0	0	3	5	5	7	13	16	18	41	17	13	7	11	8.90%
C19-C20	Rectum	93	0	0	0	0	0	0	4	4	6	11	9	11	22	8	7	8	3	5.30%
C21	Anus	14	0	0	0	0	0	0	0	0	1	2	0	0	3	1	1	2	0	0.80%
C22	Liver	55	0	1	1	0	0	0	1	3	3	1	5	9	7	7	6	5	6	3.10%
C23-C24	Gallbladder etc.	31	0	0	0	0	0	1	2	2	2	3	3	9	5	0	4	0	0	1.80%
C25	Pancreas	27	0	0	0	0	0	0	0	0	2	3	4	0	6	5	1	3	3	1.50%
C30-C31	Nose, Sinuses etc.	11	0	0	0	0	0	0	0	3	1	0	3	1	1	2	0	0	0	0.60%
C32	Larynx	23	0	0	0	0	0	0	0	1	0	2	5	4	1	3	2	0	0	1.30%
C33-C34	Trachea, Bronchus, Lung	106	0	0	0	0	0	0	1	2	2	6	13	21	18	16	14	8	5	6.00%
C37-C38	Other Thoracic Organs	11	0	0	0	0	1	2	0	1	0	0	2	1	2	1	1	0	0	0.60%
C40-C41	Bone	27	0	1	2	1	3	5	3	2	0	1	2	4	2	0	0	1	0	1.50%
C43	Melanoma of Skin	17	0	0	0	0	0	0	0	0	1	3	2	0	5	1	2	3	0	1.00%
C44	Other Skin	125	0	0	0	0	0	2	4	5	5	6	16	22	28	17	11	7	2	7.10%
C45	Mesothelioma	5	0	0	0	0	0	0	1	0	0	1	0	0	0	1	2	0	0	0.30%
C46	Kaposi Sarcoma	2	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0.10%
C47-C49	Connective, Soft Tissue	25	0	1	1	1	1	0	5	2	4	1	4	1	2	1	0	1	0	1.40%
C50	Breast	15	0	0	0	0	0	0	0	2	3	1	1	3	0	2	3	0	0	0.90%
C60	Penis	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.10%
C61	Prostate	108	0	0	0	0	0	0	0	0	0	1	5	7	21	22	23	13	16	6.10%
C62	Testis	37	0	1	0	0	0	3	4	10	8	3	3	3	1	0	0	1	0	2.10%
C63	Other Male Genital	2	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0.10%
C64	Kidney	65	0	2	0	0	0	0	1	3	6	8	6	12	13	6	1	6	1	3.70%
C65	Renal Pelvis	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.10%
C66	Ureter	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.10%
C67	Bladder	99	0	0	0	0	0	1	0	2	5	6	8	21	13	19	9	6	9	5.60%
C68	Other Urinary Organs	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.10%
C69	Eye	6	0	2	0	0	0	0	1	0	0	1	0	1	0	0	0	0	1	0.30%
C70-C72	Brain, Nervous System	69	0	4	4	4	2	2	7	6	4	6	12	8	5	1	3	1	0	3.90%
C73	Thyroid	66	0	0	0	0	0	3	5	6	9	13	7	9	2	8	3	0	1	3.80%
C74	Adrenal Gland	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.10%
C75	Other Endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C81	Hodgkin Disease	47	0	1	2	4	8	6	4	7	1	7	2	3	0	2	0	0	0	2.70%
C82-C85-C96	Non-Hodgkin Lymphoma	120	0	2	3	1	3	5	12	11	14	12	17	12	8	10	2	7	1	6.80%
C88	Immunoproliferative Disease	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.10%
C90	Multiple Myeloma	20	0	0	0	0	0	0	2	1	1	1	0	6	4	3	0	0	2	1.10%
C91	Lymphoid Leukemia	40	0	7	4	1	1	1	1	1	3	3	2	10	1	2	1	1	1	2.90%
C92-C94	Myceloid Leukemia	43	0	0	1	1	2	3	1	2	4	7	5	4	4	3	4	1	2	2.40%
C95	Leukemia Unspecified	9	0	0	1	1	0	0	1	1	2	1	0	1	0	0	0	0	1	0.50%
Other	Other & Unspecified	69	0	1	1	2	1	1	3	6	5	3	10	9	13	8	5	1	1	3.90%
All	All Sites Total	1759	0	26	19	17	21	43	75	103	116	147	199	249	256	184	137	92	75	100.00%
Not C44	All Sites but C44	1634	0	26	19	17	21	41	71	98	111	141	183	227	228	167	126	85	73	92.90%

Table 5.4.2 - Number of Cancer Cases Among Non-Saudi Females by Primary Site and Age Groups, 2013

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total (%)
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C01-C02	Tongue	8	0	0	0	0	0	0	0	1	0	0	1	1	1	4	0	0	0	0.50%
C03-C06	Mouth	7	0	0	0	0	0	0	1	0	0	1	0	0	0	3	0	1	0	0.40%
C07-C08	Salivary Glands	5	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0.30%
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C11	Nasopharynx	12	0	1	0	0	0	1	0	1	2	0	3	0	1	1	0	1	1	0.80%
C12-C13	Hypopharynx	3	0	0	0	0	0	0	1	0	0	0	0	0	0	2	0	0	0	0.20%
C14	Pharynx Unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C15	Oesophagus	15	0	0	0	0	0	0	0	2	0	2	6	1	1	1	1	0	1	0.90%
C16	Stomach	30	0	0	0	0	0	0	2	3	3	6	2	4	3	2	2	1	2	1.90%
C17	Small Intestine	8	0	0	0	0	0	0	1	0	0	2	1	2	1	0	1	0	0	0.50%
C18	Colon	63	0	0	0	0	0	0	3	3	4	10	8	7	6	13	3	3	3	3.90%
C19-C20	Rectum	54	0	0	0	0	0	1	3	4	4	7	4	14	5	3	2	3	4	3.40%
C21	Anus	6	0	0	0	0	0	0	1	0	0	0	0	0	3	1	1	0	0	0.40%
C22	Liver	18	0	0	0	0	0	1	0	0	1	1	2	0	3	6	2	0	2	1.10%
C23-C24	Gallbladder etc.	15	0	0	0	0	0	0	0	0	0	0	2	3	2	3	4	1	0	0.90%
C25	Pancreas	14	0	0	0	0	0	0	0	3	0	0	0	1	5	1	3	1	0	0.90%
C30-C31	Nose, Sinuses etc.	2	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	1	0.10%
C32	Larynx	3	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	0	0	0.20%
C33-C34	Trachea, Bronchus, Lung	24	0	0	0	0	0	0	0	1	1	2	1	4	4	5	2	3	1	1.50%
C37-C38	Other Thoracic Organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C40-C41	Bone	14	0	1	0	7	2	0	0	1	0	0	0	2	1	0	0	0	0	0.90%
C43	Melanoma of Skin	3	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0.20%
C44	Other Skin	33	0	0	0	0	0	0	1	3	3	3	3	2	3	4	3	4	4	2.10%
C45	Mesothelioma	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0.10%
C46	Kaposi Sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C47-C49	Connective, Soft Tissue	26	0	1	1	2	1	0	2	5	1	2	1	2	4	3	0	1	0	1.60%
C50	Breast	646	0	0	0	0	0	5	13	42	82	111	106	99	71	48	33	22	14	40.50%
C51	Vulva	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0.10%
C52	Vagina	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C53	Cervix Uteri	60	0	0	0	0	0	0	1	8	4	10	9	5	7	5	4	2	4	3.80%
C54	Corpus Uteri	48	0	0	0	0	0	0	1	0	6	5	2	6	8	9	6	3	2	3.00%
C55	Uterus Unspecified	13	0	0	0	0	0	0	0	0	0	2	1	3	1	1	0	2	0	0.80%
C56	Ovary	57	0	0	0	0	1	1	3	4	8	6	8	8	6	2	6	2	2	3.60%
C57	Other Female Genital	4	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	1	0.30%
C58	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C64	Kidney	26	0	6	0	1	0	1	1	1	0	3	3	6	1	1	1	1	0	1.60%
C65	Renal Pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C67	Bladder	10	0	0	0	0	0	0	0	0	2	1	1	1	1	1	2	1	0	0.60%
C68	Other Urinary Organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C69	Eye	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.10%
C70-C72	Brain, Nervous System	32	0	2	7	2	1	1	6	2	0	0	2	0	1	4	4	0	0	2.00%
C73	Thyroid	118	0	0	0	0	1	3	21	17	22	16	12	12	6	2	2	2	2	7.40%
C74	Adrenal Gland	4	0	1	0	0	1	0	0	0	0	0	0	1	0	0	1	0	0	0.30%
C75	Other Endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.00%
C81	Hodgkin Disease	29	0	0	1	2	2	3	4	6	5	1	1	1	2	0	1	0	0	1.80%
C82-C85/C96	Non-Hodgkin Lymphoma	59	0	2	1	1	2	0	3	4	7	8	6	3	5	6	4	3	4	3.70%
C88	Immunoproliferative Disease	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.10%
C90	Multiple Myeloma	11	0	0	0	0	0	0	0	0	1	2	0	1	3	1	1	1	1	0.70%
C91	Lymphoid Leukemia	29	0	9	6	1	2	0	0	1	1	2	1	2	1	0	1	0	2	1.80%
C92-C94	Myeloid Leukemia	20	0	1	0	0	0	2	3	4	2	1	2	2	2	1	0	0	0	1.30%
C95	Leukemia Unspecified	7	0	0	2	0	2	0	0	0	0	2	0	0	0	0	0	0	1	0.40%
Other	Other & Unspecified	53	0	1	0	0	0	0	1	4	7	4	9	3	10	3	4	3	4	3.30%
All	All Sites Total	1597	0	25	19	16	15	21	74	121	169	212	200	200	172	135	100	61	57	100.00%
Not C44	All Sites but C44	1564	0	25	19	16	15	21	73	118	166	209	197	198	169	131	97	57	53	97.90%

Table 5.4.3 - Age-Specific Rate (ASR), Age-Standardized Incidence Rate (ASR) Among Non-Saudi Males (per 100,000) by Primary Site and Age Groups, 2013

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	1	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0
C01-C02	Tongue	26	0	0	0	0	0	0	0	0	0.2	0.2	0.7	0.7	1.2	4.1	2.5	16.9	6.2	0.4	0.8
C03-C06	Mouth	21	0	0.3	0	0	0	0	0.2	0.1	0.3	0	0.7	0.7	0.4	1.6	2.5	5.6	6.2	0.3	0.5
C07-C08	Salivary Glands	13	0	0	0	0	0	0	0	0	0.1	0.5	0.3	0.9	0.4	0	0	0	0	0.2	0.1
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C10	Other Oropharynx	2	0	0	0	0	0	0	0	0	0	0	0	0.4	0.8	0	0	0	0	0	0
C11	Nasopharynx	40	0	0	0	2.1	0.6	0.3	0.2	0.4	1.1	1.1	2.3	0.8	5	0	0	0	0	0.6	0.7
C12-C13	Hypospharynx	1	0	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0
C14	Pharynx Unspecified	3	0	0	0	0	0	0	0	0	0.1	0.2	0	0	0	0	0	0	0	0	0
C15	Oesophagus	15	0	0	0	0	0	0.4	0.1	0.2	0.1	0.3	0.2	0	1.6	2.5	5.6	12.3	0.2	0.6	0.6
C16	Stomach	68	0	0	0	0.3	0	0.2	0.4	0.3	0.8	1.4	2.2	3.1	5.7	20	16.9	24.6	1	1	2.1
C17	Small Intestine	19	0	0	0	0	0	0	0.2	0	0.3	1.1	1.2	0.8	12.5	0	6.2	0.3	0.3	0.7	0.7
C18	Colon	156	0	0	0	1.2	1	0.8	0.4	0.5	1.3	2.2	4	15.8	13.9	32.5	39.4	67.7	2.3	2.3	5
C19-C20	Rectum	93	0	0	0	0	0	0.8	0.4	0.5	1.1	1.3	2.4	8.5	6.5	17.5	45	18.5	1.4	1.4	2.8
C21	Anus	14	0	0	0	0	0	0	0.2	0.1	0.2	0	0.7	1.5	0.8	2.5	11.3	0	0.2	0.4	0.4
C22	Liver	55	0	0.3	0.3	0	0	0.2	0.3	0.2	0.1	0.7	2	2.7	5.7	15	28.2	36.9	0.8	0.8	2.4
C23-C24	Gallbladder etc.	31	0	0	0	0	0	0.4	0.4	0.2	0.2	0.3	0.4	2	1.9	0	10	0	0	0.5	0.6
C25	Pancreas	27	0	0	0	0	0	0	0	0.2	0.3	0.6	0	2.3	4.1	2.5	16.9	18.5	0.4	0.4	1.1
C30-C31	Nose, Sinuses etc.	11	0	0	0	0	0	0	0.3	0.1	0	0.4	0.2	0.4	1.6	0	0	0	0	0.2	0.1
C32	Larynx	23	0	0	0	0	0	0	0	0.1	0	0.2	0.7	1.1	1.5	0.8	7.5	11.3	0	0.3	0.7
C33-C34	Trachea, Bronchus, Lung	106	0	0	0	0	0	0.2	0.2	0.2	0.2	0.6	1.8	4.7	7	13.1	35	45	30.8	1.6	3.8
C37-C38	Other Thoracic Organs	11	0	0	0	0.4	0.8	0	0	0.1	0	0	0.3	0.2	0.8	0.8	2.5	0	0	0.2	0.3
C40-C41	Bone	27	0	0.3	0.6	0.3	1.3	2.1	0.6	0.2	0	0.1	0.3	0.9	0.8	0	0	5.6	0	0.4	0.7
C43	Melanoma of Skin	17	0	0	0	0	0	0	0	0	0.1	0.3	0.3	0	1.9	0.8	5	16.9	0	0.3	0.6
C44	Other Skin	125	0	0	0	0	0	0.8	0.8	0.5	0.4	0.6	2.2	4.9	10.8	13.9	27.5	39.4	1.9	1.9	3.5
C45	Mesothelioma	5	0	0	0	0	0	0	0.2	0	0	0.1	0	0	0.8	5	0	0	0	0.1	0.2
C46	Kaposi Sarcoma	2	0	0	0	0	0	0	0	0.1	0	0	0	0.2	0	0	0	0	0	0	0
C47-C49	Connective, Soft Tissue	25	0	0.3	0.3	0.3	0.4	0	1	0.2	0.3	0.1	0.6	0.2	0.8	0.8	0	5.6	0	0.4	0.5
C50	Breast	15	0	0	0	0	0	0	0	0.2	0.2	0.1	0.7	0	1.6	7.5	0	0	0.2	0.2	0.4
C60	Penis	1	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0
C61	Prostate	108	0	0	0	0	0	0	0	0	0	0.1	0.7	1.6	8.1	18	57.5	73.2	98.5	1.6	6.3
C62	Testis	37	0	0.3	0	0	0	1.2	0.8	1.1	0.7	0.3	0.4	0.7	0.4	0	0	5.6	0	0.6	0.5
C63	Other Male Genital	2	0	0	0	0	0	0	0	0.1	0	0	0	0.2	0	0	0	0	0	0	0
C64	Kidney	65	0	0.6	0	0	0	0	0.2	0.3	0.5	0.8	0.8	2.7	5	4.9	2.5	33.8	6.2	1	1.6
C65	Renal Pelvis	1	0	0	0	0	0	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0
C66	Ureter	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.8	0	0	0	0	0
C67	Bladder	99	0	0	0	0	0	0.4	0	0.2	0.4	0.6	1.1	4.7	5	15.5	22.5	33.8	55.4	1.5	3.7
C68	Other Urinary Organs	1	0	0	0	0	0	0	0	0	0	0	0	0.4	0	0	0	0	0	0	0
C69	Eye	6	0	0.6	0	0	0	0	0.2	0	0	0.1	0	0.2	0	0	0	0	6.2	0.1	0.2
C70-C72	Brain, Nervous System	69	0	1.2	1.2	1.3	0.9	0.8	1.5	0.6	0.3	0.6	1.7	1.8	1.9	0.8	7.5	5.6	0	1	1.4
C73	Thyroid	66	0	0	0	0	0	1.2	1	0.6	0.7	1.3	1	2	0.8	6.5	7.5	0	6.2	1	1.1
C74	Adrenal Gland	2	0	0.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1
C75	Other Endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C81	Hodgkin Disease	47	0	0.3	0.6	1.3	3.5	2.5	0.8	0.8	0.1	0.7	0.3	0.7	0	1.6	0	0	0	0.7	1
C82-C85,C96	Non-Hodgkin Lymphoma	120	0	0.6	0.9	0.3	1.3	2.1	2.5	1.2	1.2	1.2	2.4	2.7	3.1	8.2	5	39.4	6.2	1.8	2.7
C88	Immunoproliferative Disease	1	0	0	0	0	0	0	0	0	0	0	0	0.2	0	0	0	0	0	0	0
C90	Multiple Myeloma	20	0	0	0	0	0	0.4	0.1	0.1	0.1	0.1	0	1.3	1.5	2.5	0	0	12.3	0.3	0.5
C91	Lymphoid Leukemia	40	0	2.1	1.2	0.3	0.4	0.4	0.2	0.1	0.2	0.3	0.3	2.2	0.4	1.6	2.5	5.6	6.2	0.6	1.1
C92-C94	Myeloid Leukemia	43	0	0	0.3	0.9	1.2	0.2	0.2	0.2	0.3	0.7	0.7	0.9	1.5	2.5	10	5.6	12.3	0.6	1.2
C95	Leukemia Unspecified	9	0	0	0.3	0.3	0	0	0.2	0.1	0.2	0.1	0	0.2	0	0	0	0	6.2	0.1	0.2
Other	Other & Unspecified	69	0	0.3	0.3	0.7	0	0.4	0.6	0.6	0.4	0.3	1.4	2	5	6.5	12.5	5.6	6.2	1	1.5
All	All Sites Total	1759	0	8	6	6	9	18	16	11	10	15	28	55	99	150	343	518	462	26.5	51.9
Not C44	All Sites but C44	1634	0	8	6	6	9	17	15	11	9	15	26	50	88	136	315	479	449	24.6	48.5

Table 5.4.4 - Age-Specific Rate (ASR), Age-Standardized Incidence Rate (ASR) Among Non-Saudi Females (per 100,000) by Primary Site and Age Groups, 2013

ICD (10th)	Site	All Ages	Age Unk	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Crude Rate	ASR World
C00	Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C01-C02	Tongue	8	0	0	0	0	0	0	0	0.3	0	0	0.7	1.4	2.1	12.9	0	0	0	0.3	0.7
C03-C06	Mouth	7	0	0	0	0	0	0	0.4	0	0	0.3	0	0	2.1	0	19.6	0	8.1	0.2	0.9
C07-C08	Salivary Glands	5	0	0	0	0	0	0.4	0.3	0	0	0.3	0	0	0	0	0	0	0	0.2	0.2
C09	Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C11	Nasopharynx	12	0	0.3	0	0	0	0.5	0	0.3	0.4	0	2.2	0	2.1	3.2	0	8.8	8.1	0.4	0.8
C12-C13	Hypopharynx	3	0	0	0	0	0	0	0.4	0	0	0	0	0	0	6.5	0	0	0	0.1	0.3
C14	Pharynx Unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Oesophagus	15	0	0	0	0	0	0	0	0.5	0	0.6	4.4	1.4	2.1	3.2	6.5	0	8.1	0.5	1
C16	Stomach	30	0	0	0	0	0	0	0.8	0.8	0.6	1.8	1.5	5.6	6.2	6.5	13	8.8	16.3	1	2
C17	Small Intestine	8	0	0	0	0	0	0	0.4	0	0	0.6	0.7	2.8	2.1	0	6.5	0	0.3	0.3	0.5
C18	Colon	63	0	0	0	0	0	1.2	0.8	0.9	2.9	5.8	9.9	12.3	42.1	19.6	26.3	24.4	2	5	5
C19-C20	Rectum	54	0	0	0	0	0	0.5	1.2	1.1	0.9	2.1	2.9	19.7	10.3	9.7	13	26.3	32.6	1.8	3.9
C21	Anus	6	0	0	0	0	0	0.4	0	0	0	0	0	0	6.2	3.2	6.5	0	0.2	0.2	0.6
C22	Liver	18	0	0	0	0	0	0.5	0	0	0.2	0.3	1.5	0	6.2	19.4	13	0	16.3	0.6	1.9
C23-C24	Gallbladder etc.	15	0	0	0	0	0	0	0	0	0	0	1.5	4.2	4.1	9.7	26.1	8.8	0	0.5	1.8
C25	Pancreas	14	0	0	0	0	0	0	0	0.8	0	0	0.7	0	10.3	3.2	19.6	8.8	0	0.5	1.4
C30-C31	Nose, Sinuses etc.	2	0	0	0	0	0	0.5	0	0	0	0	0	0	0	0	0	0	8.1	0.1	0.2
C32	Larynx	3	0	0	0	0	0	0	0	0	0	0	0	1.4	0	0	13	0	0	0.1	0.5
C33-C34	Trachea, Bronchus, Lung	24	0	0	0	0	0	0	0	0.3	0.2	0.6	0.7	5.6	8.2	16.2	13	26.3	8.1	0.8	2.4
C37-C38	Other Thoracic Organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C40-C41	Bone	14	0	0.3	0	2.5	0.9	0	0	0.3	0	0	0	2.8	2.1	0	0	0	0	0.5	0.6
C43	Melanoma of Skin	3	0	0	0	0	0	0.4	0	0	0	0	0.7	0	0	3.2	0	0	0	0.1	0.2
C44	Other Skin	33	0	0	0	0	0	0	0.4	0.8	0.6	0.9	2.2	2.8	6.2	12.9	19.6	35.1	32.6	1.1	3.1
C45	Mesothelioma	2	0	0	0	0	0	0	0	0	0	0	0	0	2.1	0	0	8.8	0	0.1	0.3
C46	Kaposi Sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C47-C49	Connective, Soft Tissue	26	0	0.3	0.3	0.7	0.5	0	0.8	1.3	0.2	0.6	0.7	2.8	8.2	9.7	0	8.8	0	0.8	1.4
C50	Breast	646	0	0	0	2.7	5.2	11	17.7	32.6	77.3	139.6	146.1	155.4	215.2	192.9	114.1	21	40.6	21	40.6
C51	Vulva	1	0	0	0	0	0	0	0	0	0	0.3	0	0	0	0	0	0	0	0	0
C52	Vagina	3	0	0	0	0	0	0	0	0	0	0	0	1.4	2.1	0	6.5	0	0	0	0
C53	Cervix Uteri	60	0	0	0	0	0	0.5	0.4	2.1	0.9	2.9	6.6	7	14.4	16.2	26.1	17.5	32.6	1.9	4.2
C54	Corpus Uteri	48	0	0	0	0	0	0.4	0	1.3	1.5	1.5	8.5	16.5	29.1	39.1	26.3	16.3	1.6	4.6	4.6
C55	Uterus Unspecified	13	0	0	0	0	0	0	0	0.6	0.7	0.6	0.7	4.2	2.1	3.2	0	17.5	0	0.4	0.9
C56	Ovary	57	0	0	0	0	0.5	0.5	1.2	1.1	1.7	1.8	5.8	11.3	12.3	6.5	39.1	17.5	16.3	1.9	4
C57	Other Female Genital	4	0	0	0	0	0	0	0	0	0	0	0.7	2.8	0	0	0	8.1	0.1	0.1	0.3
C58	Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C64	Kidney	26	0	1.9	0	0.4	0	0.5	0.4	0.3	0	0.9	2.2	8.5	2.1	3.2	6.5	8.8	0	0.8	1.5
C65	Renal Pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C67	Bladder	10	0	0	0	0	0	0	0	0.4	0.3	0.7	1.4	2.1	2.1	3.2	13	8.8	0	0.3	0.9
C68	Other Urinary Organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Eye	1	0	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C70-C72	Brain, Nervous System	32	0	0.6	2.1	0.7	0.5	2.4	0.5	0	0	0	1.5	0	2.1	12.9	26.1	0	0	0	2.1
C73	Thyroid	118	0	0	0	0	0.5	1.6	8.5	4.5	4.7	4.7	8.7	16.9	12.3	6.5	13	17.5	16.3	3.8	4.9
C74	Adrenal Glands	4	0	0.3	0	0	0.5	0	0	0	0	0	0	1.4	0	0	6.5	0	0	0.1	0.3
C75	Other Endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C81	Hodgkin Disease	29	0	0	0.3	0.7	0.9	1.6	1.6	1.6	1.1	0.3	0.7	1.4	4.1	0	6.5	0	0	0.9	1.1
C82-C85,C86	Non-Hodgkin Lymphoma	59	0	0.6	0.3	0.4	0.9	0	1.2	1.1	1.5	2.3	4.4	4.2	10.3	19.4	26.1	26.3	32.6	1.9	4.2
C88	Immunoproliferative Disease	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	11	0	0	0	0	0	0	0	0.2	0.6	0	0	1.4	6.2	3.2	6.5	8.8	8.1	0.4	1
C91	Lymphoid Leukemia	29	0	2.9	1.8	0.4	0.9	0	0.3	0.2	0.6	0.7	2.8	2.1	0	6.5	0	16.3	0.9	1.5	1.5
C92-C94	Myeloid Leukemia	20	0	0.3	0	0	1.1	1.2	1.1	0.4	0.3	1.5	2.8	4.1	0	3.2	0	0	0.6	0.9	0.9
C95	Leukemia Unspecified	7	0	0	0.6	0	0.9	0	0	0	0	0.6	0	0	0	0	0	0	8.1	0.2	0.3
Other	Other & Unspecified	53	0	0.3	0	0	0	0.4	1.1	1.5	1.2	6.6	4.2	20.6	9.7	26.1	26.3	32.6	1.7	4.1	4.1
All	All Sites Total	1597	0	8	6	6	7	11	30	32	36	62	146	282	354	437	652	535	464	51.9	107.8
Not C44	All Sites but C44	1554	0	8	6	6	7	11	29	31	36	61	144	279	348	424	633	500	432	50.8	104.7

Table 5.5.1 Number Of New Cases by Primary Site and Years among Saudi Males, 1994-2013

ICD (10th)	Site	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
C00	Lip	7	2	5	5	4	2	6	1	5	5	8	6	6	12	9	5	8	8	4	8
C01-C02	Tongue	32	15	20	24	13	25	29	14	23	29	33	38	38	40	32	42	53	44	42	49
C03-C06	Mouth	24	23	30	25	24	27	24	27	26	26	38	29	29	39	39	42	45	41	37	45
C07-C08	Salivary Glands	4	10	6	11	7	12	8	16	14	10	14	15	17	20	17	19	11	14	8	23
C09	Tonsil	4	9	2	4	6	2	1	4	5	5	2	3	0	4	2	0	2	4	2	3
C10	Other Oropharynx	2	3	3	1	1	3	0	3	3	0	2	3	0	2	2	1	2	3	4	3
C11	Nasopharynx	78	59	86	99	109	96	88	121	84	88	101	114	97	93	121	93	131	121	111	136
C12-C13	Hypopharynx	10	10	18	7	6	6	5	8	6	7	7	10	9	14	5	6	9	9	6	10
C14	Pharynx Unspecified	0	2	0	0	1	1	0	2	2	4	4	4	3	3	3	2	3	3	1	5
C15	Oesophagus	77	71	68	60	81	53	67	62	70	68	54	57	58	70	52	69	73	76	83	66
C16	Stomach	130	129	133	108	122	103	124	126	146	182	150	160	169	169	165	205	165	162	186	195
C17	Small Intestine	10	8	11	15	15	13	15	13	17	15	22	23	22	28	31	30	27	35	34	45
C18	Colon	61	87	72	85	104	101	115	120	152	177	202	260	231	270	292	344	303	378	391	444
C19-C20	Rectum	83	66	66	66	64	89	82	108	123	143	173	192	181	203	195	274	238	279	284	292
C21	Anus	10	9	7	8	6	5	10	12	14	11	11	16	8	12	12	22	18	11	23	17
C22	Liver	299	298	276	268	326	296	290	274	292	283	277	289	319	333	338	328	329	330	344	339
C23-C24	Gallbladder etc.	24	32	25	22	28	25	27	39	41	39	26	37	48	54	54	58	51	73	68	77
C25	Pancreas	50	49	53	44	60	58	68	53	75	85	82	97	101	128	102	130	114	128	155	130
C30-C31	Nose, Sinuses etc.	5	6	10	4	10	13	5	9	14	10	10	14	9	10	14	5	9	8	17	6
C32	Larynx	49	48	43	40	46	43	44	53	32	60	55	51	64	55	61	58	48	70	59	78
C33-C34	Trachea, Bronchus, Lung	188	183	184	162	223	203	197	189	194	201	253	280	237	325	294	287	292	343	336	326
C37-C38	Other Thoracic Organs	7	11	12	13	8	17	7	7	5	12	12	22	15	19	11	17	25	21	18	21
C40-C41	Bone	47	50	34	46	51	53	51	67	51	44	66	56	65	69	78	65	74	71	85	63
C43	Melanoma of Skin	21	8	8	8	6	7	11	9	12	10	13	14	12	17	13	13	12	16	8	13
C44	Other Skin	104	117	112	107	97	120	112	154	149	166	140	156	189	168	161	184	168	208	169	206
C45	Mesothelioma	4	4	5	5	7	2	2	5	3	6	6	6	8	12	18	5	9	12	12	7
C46	Kaposi Sarcoma	15	10	14	14	12	11	19	19	21	26	26	22	22	18	17	33	21	19	24	24
C47-C49	Connective/Soft Tissue	85	68	51	60	50	67	55	48	63	69	59	75	64	72	72	72	69	77	86	85
C50	Breast	11	15	6	12	19	12	16	12	16	16	13	15	17	20	18	24	24	16	25	21
C60	Penis	3	4	1	8	0	1	1	1	3	1	3	5	1	0	3	2	1	0	3	2
C61	Prostate	150	148	154	123	159	150	184	170	194	192	247	272	236	259	279	305	280	311	288	306
C62	Testis	32	21	25	29	38	31	35	35	45	38	46	44	40	63	74	78	78	80	82	94
C63	Other Male Genital	1	2	0	3	1	2	3	3	3	4	3	2	4	0	0	2	2	6	0	3
C64	Kidney	69	78	56	63	71	81	73	87	91	84	124	104	120	146	158	185	167	178	190	193
C65	Renal Pelvis	5	5	0	0	10	2	6	2	1	7	8	4	5	4	5	5	5	3	8	2
C66	Ureter	1	3	1	0	3	0	4	1	0	6	3	3	1	2	3	1	1	5	2	1
C67	Bladder	165	154	127	126	152	152	155	143	160	176	175	170	174	173	178	208	193	182	193	227
C68	Other Urinary Organs	1	1	1	0	1	1	0	0	1	1	1	1	0	1	1	1	3	1	1	1
C69	Eye	21	12	18	34	16	24	26	22	24	21	21	17	28	23	27	29	22	20	23	23
C70-C72	Brain, Nervous system	131	99	126	122	101	120	139	120	148	155	155	141	155	139	162	156	148	170	175	180
C73	Thyroid	73	61	58	73	84	84	77	74	91	87	95	93	121	122	136	150	149	154	193	182
C74	Adrenal Gland	8	9	8	8	4	9	10	7	6	15	6	10	21	16	16	20	29	13	18	16
C75	Other Endocrine	2	3	5	1	2	2	1	4	1	5	3	6	5	4	9	6	0	8	9	0
C81	Hodgkin Disease	104	105	105	97	133	118	125	136	122	145	176	167	178	179	187	199	194	184	194	239
C82-C85/C96	Non-Hodgkin Lymphoma	272	214	231	226	283	268	265	246	272	329	351	351	363	425	381	436	407	432	424	435
C88	Immunoproliferative Disease	0	0	0	1	0	1	0	0	0	1	2	0	0	0	0	1	0	1	0	0
C90	Multiple Myeloma	59	41	30	36	48	37	46	36	30	39	46	60	53	46	40	62	61	50	71	64
C91	Lymphoid Leukemia	151	118	146	139	150	137	152	158	146	165	155	166	163	195	167	194	187	202	229	233
C92-C94	Myeloid Leukemia	94	90	84	103	94	109	90	129	115	90	119	109	130	119	144	147	156	148	168	144
C95	Leukemia Unspecified	10	5	5	5	8	6	14	13	12	14	13	15	26	27	37	16	16	16	21	25
Other	Other & Unspecified	147	122	98	131	140	138	126	133	153	140	149	179	181	169	155	162	161	169	153	174
All	All sites Total	2941	2697	2640	2647	3004	2938	3014	3095	3248	3505	3766	3986	4043	4391	4390	4798	4683	4913	5067	5281
Not C44	All sites but C44	2837	2580	2528	2540	2907	2818	2902	2941	3059	3339	3626	3830	3854	4223	4229	4614	4425	4705	4898	5075

Table 5 5 2 Number Of New Cases by Primary Site and Years among Saudi Females 1994-2013

ICD (10th)	Site	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
C00	Lip	3	3	4	2	1	1	4	3	6	5	8	6	4	5	6	8	5	7	4	7
C01-C02	Tongue	21	20	28	28	29	31	25	19	30	30	29	23	25	38	30	39	43	52	51	46
C03-C06	Mouth	23	38	37	22	32	39	25	27	29	30	21	43	36	51	46	37	48	46	33	51
C07-C08	Salivary Glands	8	7	6	3	11	8	14	8	6	10	12	13	14	18	17	21	15	22	28	15
C09	Tonsil	0	3	3	3	3	1	3	1	5	4	2	1	1	3	3	3	0	1	2	2
C10	Other Oropharynx	0	1	0	0	0	0	0	0	2	0	2	2	0	1	0	0	1	1	3	0
C11	Nasopharynx	38	27	39	31	37	36	23	41	41	39	45	35	44	56	50	42	40	45	45	47
C12-C13	Hypphiarynx	19	10	14	15	19	16	10	12	12	1	16	16	10	9	17	12	17	16	17	16
C14	Pharynx Unspecified	2	3	1	1	1	1	2	0	3	1	2	0	1	3	1	3	2	2	2	3
C15	Oesophagus	75	54	68	52	44	46	55	37	58	50	51	65	62	55	56	47	50	58	63	49
C16	Stomach	67	71	64	58	66	71	62	72	77	75	76	74	115	126	103	116	126	133	94	121
C17	Small Intestine	6	11	9	10	10	10	11	14	8	11	13	13	13	14	14	25	13	35	25	16
C18	Colon	65	80	85	78	72	105	108	143	134	147	179	197	246	277	308	306	306	342	304	411
C19-C20	Rectum	44	49	52	59	57	86	72	87	104	106	118	144	142	149	163	197	186	195	231	240
C21	Anus	6	3	1	3	5	2	4	2	5	9	7	8	8	12	7	16	9	15	9	7
C22	Liver	110	88	101	86	123	93	121	101	116	129	120	114	137	130	126	150	154	158	130	156
C23-C24	Gallbladder etc.	51	37	25	31	50	59	46	55	41	60	53	68	72	85	83	90	89	90	90	97
C25	Pancreas	28	30	24	25	50	41	35	35	54	41	35	52	78	53	70	87	81	77	87	103
C30-C31	Nose, Sinuses etc.	6	9	5	4	9	8	6	5	8	2	6	10	12	13	7	7	4	3	13	7
C32	Larynx	10	2	7	10	8	10	9	2	7	4	6	6	9	10	5	18	5	6	12	25
C33-C34	Trachea, Bronchus, Lung	51	55	48	53	50	47	52	57	52	64	69	87	81	91	84	106	105	109	127	109
C37-C38	Other Thoracic Organs	7	6	5	6	5	5	8	5	3	10	9	11	11	7	12	10	11	7	10	19
C40-C41	Bone	26	38	35	25	44	37	38	43	35	39	40	41	40	30	49	46	44	58	60	63
C43	Melanoma of Skin	11	7	7	2	12	8	6	18	7	9	15	9	15	18	11	8	12	15	16	10
C44	Other Skin	78	55	87	57	83	77	80	102	95	124	131	131	134	119	126	144	151	125	132	117
C45	Mesothelioma	1	0	1	1	0	4	1	1	3	7	5	6	6	3	2	10	4	4	2	2
C46	Kaposi Sarcoma	0	3	0	8	7	8	4	5	3	6	5	8	15	6	5	4	6	6	2	4
C47-C49	Connective,Soft Tissue	42	55	42	46	61	50	48	43	39	54	75	52	41	65	55	66	76	72	59	65
C50	Breast	429	434	463	464	516	514	602	565	672	713	815	952	988	1173	1215	1353	1473	1590	1542	1853
C51	Vulva	8	6	2	3	3	3	8	7	5	6	11	1	3	4	5	6	9	7	8	11
C52	Vagina	5	6	2	4	2	3	1	5	5	1	5	7	1	4	0	3	2	4	4	5
C53	Cervix Uteri	78	73	83	75	94	79	81	84	85	91	89	98	74	102	95	101	82	114	137	104
C54	Corpus Uteri	57	47	39	48	60	58	92	78	88	111	125	149	151	185	194	257	220	316	315	289
C55	Uterus Unspecified	3	2	9	10	16	12	5	13	14	15	13	18	24	29	22	31	29	41	48	51
C56	Ovary	96	100	96	114	107	101	104	111	108	123	119	147	139	147	172	179	175	198	183	194
C57	Other Female Genital	1	1	0	2	2	4	3	5	4	5	10	6	9	8	6	7	6	12	15	11
C58	Placenta	17	10	13	7	10	13	8	15	16	5	8	14	22	12	13	12	5	9	3	12
C64	Kidney	60	37	49	57	52	64	49	70	69	68	84	65	79	84	98	124	117	112	123	120
C65	Renal Pelvis	0	1	0	2	3	3	2	1	1	2	2	4	4	1	1	3	5	2	0	4
C66	Ureter	0	1	1	0	1	1	0	1	1	1	2	4	2	0	0	1	4	2	0	1
C67	Bladder	28	39	23	29	39	37	39	51	41	42	43	39	42	36	40	40	50	52	52	53
C68	Other Urinary Organs	0	0	0	0	0	1	0	0	0	0	1	1	1	0	1	0	2	0	1	2
C69	Eye	15	16	18	13	12	24	24	17	20	16	18	20	19	20	17	24	24	19	19	22
C70-C72	Brain, Nervous System	80	73	76	94	85	78	84	84	85	95	108	103	108	117	95	115	105	99	123	128
C73	Thyroid	207	218	198	210	264	282	259	258	279	368	346	391	432	459	496	576	548	646	687	702
C74	Adrenal Gland	10	6	10	11	9	10	14	8	10	14	17	9	10	9	13	11	14	5	17	13
C75	Other Endocrine	2	1	2	1	2	3	1	0	1	1	2	5	5	4	2	2	1	4	1	1
C81	Hoedkin Disease	59	69	59	57	74	76	87	78	76	114	105	104	119	135	136	154	142	157	161	164
C82-C85/C96	Non-Hodgkin Lymphoma	143	149	142	146	186	176	186	202	203	238	244	259	246	285	313	287	296	312	316	311
C88	Immunoproliferative Disease	0	0	0	1	0	1	0	1	0	1	0	0	0	0	0	1	0	0	1	1
C90	Multiple Myeloma	20	33	20	13	24	27	25	19	19	16	26	26	33	49	29	39	42	47	52	53
C91	Lymphoid Leukemia	76	89	80	82	73	95	112	86	101	93	85	86	92	117	118	137	123	142	132	161
C92-C94	Myeloid Leukemia	77	78	75	90	83	89	122	100	103	103	125	100	100	110	110	127	118	178	171	164
C95	Leukemia Unspecified	6	6	1	5	6	11	9	4	5	11	11	17	9	19	30	23	16	13	25	17
Other	Other & Unspecified	103	95	93	95	137	127	122	116	117	161	175	147	170	152	166	164	167	178	140	176
All sites Total		2381	2355	2360	2352	2750	2794	2881	2909	3107	3482	3736	4007	4115	4675	4812	5397	5378	5956	5967	6364
Not C44	All sites but C44	2303	2300	2273	2295	2667	2717	2801	2807	3012	3358	3605	3876	4115	4556	4686	5253	5227	5831	5835	6247

Table 5.5.3 Age Standardized Incidence Rate by Primary Site and Years among Saudi Males, 1994-2013

ICD (10th)	Site	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	
C00	Lip	0.2	0.1	0.1	0.1	0.1	0	0.1	0	0.1	0.1	0.2	0.1	0.1	0.2	0.2	0.1	0.1	0.1	0.1	0.1	
C01-C02	Tongue	0.9	0.5	0.6	0.6	0.3	0.6	0.8	0.3	0.5	0.6	0.8	0.9	0.8	0.8	0.6	0.8	0.8	1	0.7	0.6	0.8
C03-C06	Mouth	0.7	0.7	0.6	0.6	0.6	0.6	0.5	0.7	0.6	0.6	0.8	0.7	0.7	0.8	0.7	0.8	0.9	0.8	0.7	0.6	0.7
C07-C08	Salivary Glands	0.1	0.3	0.2	0.3	0.2	0.2	0.2	0.3	0.3	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.2	0.2	0.2	0.1	0.3
C09	Tonsil	0.1	0.2	0.1	0.1	0.1	0.1	0	0.1	0.1	0.1	0.1	0.1	0	0.1	0	0	0	0	0.1	0	0.1
C10	Other Oropharynx	0.1	0.1	0.1	0	0	0.1	0	0.1	0.1	0	0	0	0	0	0	0	0	0	0	0	0
C11	Nasopharynx	2.1	1.5	2.3	2.5	2.6	2.2	2	2.5	1.8	1.7	2	2.2	1.7	1.5	2	1.5	2	1.8	1.6	1.6	1.8
C12-C13	Hypopharynx	0.3	0.2	0.4	0.2	0.2	0.1	0.1	0.2	0.1	0.1	0.2	0.2	0.2	0.3	0.1	0.1	0.2	0.2	0.2	0.1	0.2
C14	Pharynx Unspecified	0	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0.1	0.1	0	0	0	0	0	0	0.1
C15	Esophagus	2.2	1.9	1.7	1.5	2	1.2	1.5	1.6	1.6	1.6	1.2	1.3	1.4	1.4	1	1.4	1.4	1.3	1.4	1.4	1.1
C16	Stomach	3.7	3.6	3.5	2.7	3	2.4	3	2.9	3.2	4.2	3.4	3.5	4.1	3.5	3.2	4	3.1	2.8	3.2	3.2	3.3
C17	Small Intestine	0.3	0.2	0.3	0.3	0.4	0.3	0.4	0.3	0.4	0.3	0.5	0.5	0.5	0.6	0.6	0.6	0.5	0.6	0.6	0.6	0.7
C18	Colon	1.8	2.4	1.9	2.1	2.5	2.5	2.9	2.9	3.4	4	4.4	5.8	5.3	5.4	5.4	6.5	5.5	6.6	6.5	6.5	7
C19-C20	Rectum	2.4	1.9	1.6	1.7	1.6	2.3	2	2.4	2.6	3.3	3.9	4.4	4.3	4	3.8	5.1	4.4	4.7	4.6	4.7	4.7
C21	Anus	0.3	0.2	0.2	0.2	0.2	0.1	0.3	0.3	0.3	0.3	0.4	0.2	0.3	0.2	0.2	0.4	0.3	0.2	0.4	0.2	0.2
C22	Liver	8.7	8.6	7.5	7.1	8.4	7.5	7.3	7.3	7.3	7.1	7.1	6.6	6.8	7.2	6.9	6.6	6.4	6.1	6.3	6.3	5.9
C23-C24	Gallbladder etc.	0.7	0.9	0.7	0.6	0.7	0.6	0.7	1.1	0.9	1.3	1.1	0.6	0.9	1.3	1.1	1.1	0.9	1.3	1.2	1.2	1.3
C25	Pancreas	1.4	1.3	1.5	1.2	1.5	1.4	1.6	1.3	1.7	2	2	2.2	2.6	2.7	2	2.6	2.2	2.3	2.6	2.2	2.2
C30-C31	Nose, Sinuses etc.	0.1	0.2	0.3	0.1	0.2	0.3	0.1	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.1	0.3	0.1	0.1
C32	Larynx	1.5	1.4	1.2	1.2	1.2	1.1	1.1	1.5	0.8	1.5	1.3	1.3	1.6	1.2	1.2	1.2	1.2	0.9	1.3	1.1	1.3
C33-C34	Trachea, Bronchus, Lung	5.6	5.3	4.9	4.4	5.8	5.2	5	4.8	5	5.1	5.9	6.5	6.2	6.9	6	6	5.8	6.4	5.9	5.5	5.5
C37-C38	Other Thoracic Organs	0.2	0.2	0.2	0.2	0.2	0.3	0.1	0.1	0.1	0.3	0.2	0.4	0.2	0.3	0.2	0.3	0.3	0.3	0.2	0.2	0.2
C40-C41	Bone	0.7	0.7	0.5	0.7	0.7	0.7	0.7	0.8	0.6	0.6	0.7	0.6	0.7	0.7	0.7	0.9	0.7	0.7	0.8	0.9	0.6
C43	Melanoma of Skin	0.6	0.2	0.2	0.2	0.2	0.2	0.3	0.2	0.3	0.2	0.3	0.3	0.3	0.4	0.3	0.2	0.2	0.2	0.3	0.1	0.2
C44	Other Skin	2.7	3	2.8	2.8	2.4	2.7	2.5	3.5	3.2	3.7	3	3.4	4.5	3.3	3	3.5	3.1	3.6	2.7	3.3	3.3
C45	Mesothelioma	0.1	0.1	0.2	0.1	0.2	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.4	0.1	0.2	0.2	0.2	0.1
C46	Kaposi Sarcoma	0.5	0.3	0.3	0.3	0.3	0.2	0.4	0.5	0.5	0.6	0.6	0.4	0.5	0.3	0.3	0.6	0.4	0.3	0.4	0.4	0.4
C47-C49	Connective/Soft Tissue	1.8	1.4	1	1.2	0.8	1.2	0.9	0.9	1.1	1.2	0.8	1	1	1	1	0.9	0.8	0.9	1	1	1
C50	Breast	0.3	0.4	0.1	0.3	0.5	0.3	0.4	0.3	0.4	0.4	0.3	0.3	0.4	0.4	0.3	0.3	0.4	0.4	0.3	0.4	0.3
C80	Penis	0.1	0.1	0	0.2	0	0	0	0	0.1	0	0	0.1	0.1	0	0	0	0	0	0	0	0
C81	Prostate	4	3.9	3.8	2.9	3.9	3.5	4	4.4	4.3	4.5	5.7	6.4	6.3	5.7	5.9	6.3	5.5	6	5.3	5.5	5.5
C82	Testis	0.7	0.4	0.5	0.5	0.7	0.6	0.6	0.5	0.7	0.5	0.6	0.5	0.6	0.5	0.7	0.8	0.8	0.8	0.8	0.8	0.9
C63	Other Male Genital	0	0	0	0.1	0	0	0.1	0.1	0.1	0.1	0.1	0	0	0.1	0	0	0	0	0.1	0	0.1
C64	Kidney	1.8	2	1.4	1.5	1.7	1.7	1.7	1.9	1.8	1.8	2.5	2.1	2.7	2.7	2.8	3.2	2.9	2.9	2.8	2.8	2.9
C65	Renal Pelvis	0.1	0.1	0	0	0.3	0.1	0.1	0	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0	0.1	0	0
C66	Ureter	0	0.1	0	0	0.1	0	0.1	0	0	0.2	0.1	0.1	0.1	0	0	0	0	0	0.1	0	0
C67	Bladder	4.6	4.3	3.4	3.2	3.8	3.7	3.9	3.4	3.5	4.1	4	3.7	4.2	3.5	3.7	4.1	3.6	3.3	3.2	3.8	3.8
C68	Other Urinary Organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Eye	0.5	0.2	0.3	0.5	0.2	0.4	0.3	0.5	0.4	0.3	0.4	0.3	0.4	0.3	0.3	0.4	0.3	0.2	0.3	0.3	0.3
C70-C72	Brain, Nervous System	2.9	1.8	2.4	2.2	1.6	2.1	2.3	2.1	1.9	2.5	2.5	2.2	2.2	2	2.2	2.2	1.9	2.2	2.2	2.2	2.1
C73	Thyroid	2	1.5	1.5	1.8	1.9	1.7	1.6	1.6	1.6	1.9	1.7	1.8	1.6	1.9	1.9	2.1	2.2	2.3	2.2	2.7	2.2
C74	Adrenal Gland	0.1	0.1	0.2	0.1	0	0.1	0.2	0.1	0.1	0.2	0.1	0.1	0.3	0.2	0.2	0.2	0.3	0.1	0.2	0.2	0.2
C75	Other Endocrine	0.1	0.1	0.1	0	0	0	0	0	0	0.1	0	0.1	0.1	0	0.1	0	0	0	0.1	0	0.1
C81	Hodgkin Disease	2.1	1.9	1.7	1.5	2.2	1.9	1.8	2.1	1.9	2	2.4	2.1	2.1	2.1	2.1	2.4	2.1	1.9	2	2	2.5
C82-C85/C86	Non-Hodgkin Lymphoma	6.6	5	5.5	5	6.2	6.1	5.4	5	5.2	6.4	6.2	6.5	6.7	7.1	6.2	7	6.2	6.4	6.2	6.1	6.1
C88	Immunoproliferative Disease	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	1.8	1.1	0.8	1	1.3	1	1.1	0.9	0.6	0.9	1.1	1.3	1.3	1	0.8	1.2	1.2	0.9	1.2	1	1
C91	Lymphoid Leukemia	2.2	1.8	2.1	2.1	2.3	2	2.1	2.4	2.1	2.2	2.1	2	2.5	2.4	2.1	2.4	2.1	2.3	2.6	2.4	2.4
C92-C94	Myeloid Leukemia	1.9	1.7	1.7	2	1.9	2	1.7	2.1	2	1.5	1.9	1.6	2	1.6	2	2	2	2	2	2.1	1.7
C95	Leukemia Unspecified	0.2	0.1	0.1	0.1	0.2	0.1	0.3	0.3	0.2	0.3	0.2	0.2	0.5	0.4	0.6	0.3	0.2	0.2	0.2	0.3	0.3
Other	Other & Unspecified	4	3.1	2.6	3.3	3.4	3.4	2.8	3.4	3.5	3.2	3.3	3.9	4.3	3.3	3	3	2.9	2.8	2.5	2.7	2.7
All	All sites Total	75.9	67.1	63.1	61	68.7	65	65.1	67.9	67.4	73.9	76.3	80	86.6	80.6	77	84	76.7	78.8	78.1	78.5	78.5
Not C44	All sites but C44	73.1	64.1	60.3	58.3	66.4	62.3	62.7	64.4	64.2	70.2	73.3	76.6	82.1	77.4	74	80.4	73.6	75.2	75.3	75.3	75.2

Table 5.5.4 Age Standardized Incidence Rate by Primary Site and Years among Saudi Females, 1994-2013

ICD (10th)	Site	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013
C00	Lip	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1
C01-C02	Tongue	0.7	0.7	0.9	0.8	0.9	0.9	0.6	0.5	0.7	0.7	0.7	0.7	0.5	0.6	0.6	0.7	0.8	0.9	0.8	0.7
C03-C06	Mouth	0.7	1.2	1.1	0.7	1	1.1	0.7	0.6	0.7	0.7	0.5	0.9	0.8	1	0.9	0.7	0.8	0.8	0.5	0.8
C07-C08	Salivary Glands	0.2	0.2	0.2	0.2	0.1	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.2	0.3	0.2	0.3	0.4	0.2
C09	Tonsil	0	0.1	0.1	0.1	0	0	0.1	0	0.1	0.1	0	0	0	0	0.1	0	0	0	0	0
C10	Other Oropharynx	0	0	0	0	0	0	0	0	0.1	0.1	0	0.1	0	0	0	0	0	0	0	0
C11	Nasopharynx	0.9	0.6	1	0.7	0.9	0.8	0.4	0.7	0.8	0.7	0.9	0.7	0.8	0.9	0.8	0.7	0.6	0.6	0.6	0.6
C12-C13	Hypopharynx	0.6	0.3	0.5	0.5	0.6	0.4	0.3	0.3	0.2	0	0.4	0.2	0.2	0.2	0.3	0.2	0.3	0.3	0.2	0.2
C14	Pharynx Unspecified	0	0.1	0	0	0	0	0.1	0	0.1	0	0.1	0	0	0	0	0.1	0	0	0	0
C15	Oesophagus	2.7	1.8	2.2	1.7	1.4	1.4	1.5	1	1.5	1.2	1.2	1.5	1.6	1.2	1.1	0.9	1	1	1	0.8
C16	Stomach	2.4	2.3	2.1	1.7	1.9	2	1.6	1.7	1.8	1.8	1.7	1.7	2.7	2.5	1.9	2.2	2.3	2.3	1.5	1.8
C17	Small Intestine	0.3	0.4	0.3	0.3	0.3	0.2	0.3	0.3	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.2	0.6	0.4	0.2
C18	Colon	2.3	2.7	2.6	2.3	2.2	2.8	2.6	3.4	3	3.4	4.1	4.2	5.1	4.7	5.3	5.9	5.8	5.7	5.3	6.4
C19-C20	Rectum	1.6	1.7	1.6	1.9	1.7	2.2	1.8	2	2.3	2.5	2.6	3.1	3.2	2.9	3.2	3.8	3.4	3.3	3.7	3.7
C21	Anus	0.2	0.1	0	0.1	0	0	0.1	0.1	0.1	0.2	0.1	0.2	0.2	0.2	0.1	0.3	0.2	0.3	0.2	0.1
C22	Liver	3.9	3	3.3	2.9	3.8	2.7	3.2	2.7	2.8	3.3	2.9	2.6	3.3	2.8	2.6	3	3.1	2.9	2.3	2.6
C23-C24	Gallbladder etc.	1.8	1.3	0.8	1	1.6	1.7	1.3	1.4	1.1	1.5	1.2	1.6	1.7	1.9	1.7	1.9	1.8	1.6	1.6	1.7
C25	Pancreas	1.1	1.1	0.8	0.9	1.6	1.2	0.9	0.9	1.4	1	0.9	1.2	1.9	1.2	1.5	1.8	1.6	1.4	1.5	1.7
C30-C31	Nose, Sinuses etc.	0.2	0.2	0.1	0.1	0.2	0.2	0.1	0.1	0.2	0	0.1	0.2	0.3	0.2	0.1	0.1	0.1	0.1	0.2	0.1
C32	Larynx	0.3	0.1	0.2	0.3	0.2	0.3	0.2	0.2	0.2	0.1	0.1	0.1	0.2	0.2	0.1	0.4	0.1	0.1	0.2	0.4
C33-C34	Trachea, Bronchus, Lung	1.9	2	1.5	1.6	1.5	1.4	1.5	1.5	1.4	1.5	1.6	1.9	2	1.9	1.8	2.1	2.1	1.9	2.2	1.8
C37-C38	Other Thoracic Organs	0.2	0.2	0.1	0.1	0.1	0.1	0.2	0.1	0	0.1	0.2	0.2	0.2	0.2	0.1	0.2	0.1	0.2	0.1	0.3
C40-C41	Bone	0.4	0.7	0.7	0.4	0.6	0.5	0.4	0.5	0.4	0.5	0.5	0.4	0.4	0.3	0.6	0.5	0.5	0.6	0.7	0.6
C43	Melanoma of Skin	0.3	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.4	0.2	0.2	0.2	0.2	0.2	0.3
C44	Other Skin	2.7	1.7	2.7	1.8	2.4	2.1	2	2.5	2.2	2.9	3.1	2.9	3	2.5	2.4	2.8	2.8	2.2	2.1	1.8
C45	Mesothelioma	0	0	0	0	0	0	0	0	0.1	0.2	0.1	0.1	0.1	0.1	0	0.2	0.1	0	0	0
C46	Reposit Sarcoma	0	0.1	0	0.3	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.4	0.1	0.1	0.1	0.1	0	0
C47-C49	Connective Soft tissue	0.9	1.3	1	1	1.1	1.1	0.8	0.6	0.6	0.8	1.3	0.7	0.6	0.8	0.8	0.8	1.1	0.9	0.7	0.8
C50	Breast	13.3	13	13.2	12.5	13.8	12.4	13.5	12	13.9	14.6	16.1	18.4	18.1	20.5	20.3	23.4	24.9	23.4	22.1	25.5
C51	Vulva	0.3	0.2	0.2	0.1	0.1	0.1	0.2	0.2	0.1	0	0.2	0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
C52	Vagina	0.2	0.2	0	0.2	0	0.1	0	0.1	0.1	0	0	0.2	0	0.1	0	0.1	0	0.1	0.1	0.1
C53	Cervix Uteri	2.4	2.2	2.5	2.2	2.8	2	1.9	1.8	2	1.8	1.9	1.8	2.1	1.5	1.8	1.7	1.8	1.5	1.7	1.8
C54	Corpus Uteri	2.1	1.4	1.4	1.5	2	1.6	2.5	2	2.2	2.7	3	3.5	3.8	4	4	5.4	4.6	5.8	5.4	4.9
C55	Uterus Unspecified	0.1	0.1	0.3	0.3	0.5	0.3	0.1	0.3	0.3	0.4	0.3	0.4	0.6	0.7	0.4	0.6	0.6	0.7	0.8	0.9
C56	Ovary	2.9	3	2.7	3.1	3.1	2.3	2.2	2.4	2.2	2.4	2.4	3	2.9	2.6	3.2	3.1	3	3.1	3	2.7
C57	Other Female Genital	0	0	0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.2	0.1	0.1	0.1	0.1	0.2	0.2
C58	Placenta	0.4	0.2	0.3	0.1	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.2	0.3	0.2	0.1	0.1	0.1	0.1	0	0.1
C64	Kidney	1.4	1	1.1	1.3	1.4	1.4	0.9	1.4	1.4	1.4	1.8	1.2	1.5	1.4	1.6	2	2	1.7	1.8	1.7
C65	Renal Pelvis	0	0	0	0.1	0.1	0.1	0.1	0	0	0.1	0.1	0.1	0.1	0	0	0.1	0.1	0	0	0.1
C66	Ureter	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0	0	0	0.1	0	0	0
C67	Bladder	0.9	1.1	0.7	0.9	1.2	1	1	1.3	1	1	1	0.8	1	0.7	0.8	0.8	1	1	0.9	0.9
C68	Other Urinary Organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Eye	0.3	0.3	0.4	0.2	0.2	0.4	0.4	0.3	0.4	0.3	0.3	0.3	0.3	0.3	0.2	0.3	0.3	0.2	0.2	0.3
C70-C72	Brain, Nervous System	1.4	1.5	1.4	1.9	1.5	1.4	1.5	1.5	1.3	1.6	1.7	1.4	1.7	1.7	1.4	1.7	1.4	1.2	1.5	1.5
C73	Thyroid	5.5	5.2	4.7	4.9	5.8	5.6	4.8	4.7	4.8	6.3	5.7	6.2	6.6	6.4	7	8.1	7.5	8.1	8.3	8.1
C74	Adrenal Gland	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.2	0	0.2	0.1
C75	Other Endocrine	0.1	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0	0	0	0	0.1	0	0
C81	Hodgkin Disease	1.4	1.3	1.1	1.1	1.3	1.2	1.3	1.2	1.1	1.6	1.4	1.3	1.6	1.6	1.6	1.8	1.6	1.7	1.6	1.5
C82-C85/C86	Non-Hodgkin Lymphoma	4.2	4.2	4.1	3.9	5	4.1	4.1	4.4	4.4	5	4.8	5.2	5.1	5.1	5.6	5.1	5.2	4.8	4.7	4.6
C88	Immunoproliferative Disease	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C90	Multiple Myeloma	0.8	1.2	0.7	0.4	0.7	0.8	0.7	0.5	0.5	0.4	0.6	0.6	0.8	1	0.6	0.8	0.9	0.8	0.9	0.8
C91	Lymphoid Leukemia	1	1.6	1.2	1.1	1.1	1.3	1.3	1.2	1.1	1.1	1.1	1.3	1.3	1.4	1.4	1.6	1.4	1.6	1.4	1.7
C92-C94	Myeloid Leukemia	1.7	1.6	1.6	1.6	1.5	1.6	1.7	1.7	1.8	1.7	1.9	1.6	2.2	1.6	1.5	1.8	1.8	1.8	2.2	2.1
C95	Leukemia Unspecified	0.1	0.1	0	0.1	0.1	0.3	0.2	0.1	0.1	0.2	0.2	0.2	0.2	0.3	0.4	0.4	0.2	0.2	0.3	0.2
C95	Other & Unspecified	3.5	3.1	2.8	2.8	4.1	3.3	3.1	3	2.7	3.8	4	3.2	4	3.1	3.3	3.1	3.1	3	2.3	2.7
All	All sites Total	70.6	66.9	64.4	62.2	72	65.6	63.4	62.3	64.1	71.2	74.6	77.8	84.4	82.6	82.7	93.1	91.2	90.1	86.7	89.4
Net C44	All sites but C44	67.9	65.1	61.7	60.3	68.6	63.6	61.4	59.8	61.9	68.3	71.6	74.9	81.4	80.2	80.3	90.4	88.4	88	84.6	87.6



## Acknowledgment

We would like to express our deepest gratitude to the following members of SCR scientific committee and staff of the registry for their invaluable contribution and support.

### SCR Scientific Committee Members

Dr. Ali Saeed Al-Zahrani	(Chairman)
Dr. Hind Mohammed Al-Mutlaq	(Acting Director, SCR)
Dr. Mushabab Ali Asiri	(Regional Director, Central Region)
Dr. Hassnah Ali Al-Ghamdi	(Regional Director, Western Region)
Dr. Amal Mohammed Al-Behani	(Regional Director, Madinah & Northern Region)
Dr. Abdurahman Ali Al-Shehri	(Regional Director, Southern Region)
Prof. Hassan Yousef Al-Idrisi	(Regional Director, Eastern Region)
Dr. Mohammed Yahya Saeedi	(Ministry of Health)
Dr. Amer Naeem Radwi	(Health Affairs- Ministry of National Guard)
Dr. Abdulaziz Saleh Abahussin	(Medical Services- Security Forces)
Dr. Ali Matar Al-Zahrani	(Medical Services- Military Forces)
Dr. Shouki Mohammed Bazarbshi	(King Faisal Specialist Hospital & Research Center)
Dr. Abdulziz Abdullah Al-Saif	(Ministry of Education, King Saud University)
Dr. Abdulrahem Toran Gari	(Private Hospital)
Dr. Nasser Abdurahman Al-Hamdan	(Ministry of Health, King Fahad Medical City)

### Main Office

- \* Dr. Hind Al-Mutlaq- Acting Director
- \* Mr. Abdurahman Al-Biaby
- \* Ms. Wafa Al-Zahrani
- \* Mr. Zeyad Al-Shahrani
- \* Ms. Mona Al-Shridah
- \* Ms. Malak Al-Jamaan
- \* Ms. Tahani Al-Shumrani

### Central Region

- \* Dr. Mushabab Asiri - Director
- \* Mr. Mohammed Hayder (CTR)
- \* Mr. Mohamed Kamal Abdulqader (CTR)
- \* Mr. Iman Daggal
- \* Dr. Omar Ahmed (CTR)
- \* Mr. Sheikh Meera Mohiuddin
- \* Ms. Herminia Bersamin

### Western Region

- \* Dr. Hassnah Al-Ghamdi- Director
- \* Mr. Sameer Kaifah
- \* Mr. Nabil Bahri
- \* Mr. Hamzah Al-Aidrous
- \* Mr. Mohammad Aden
- \* Ms. Ittra Hiali
- \* Ms. Elizabeth Aunor
- \* Mr. Ahmed Al-Nemari
- \* Mr. Waleed Al-Qahtani

### Eastern Region

- \* Prof. Hassan Al-Idrisi- Director
- \* Mr. Abdulmajeed Alam
- \* Mr. Zafar Armani (CTR)
- \* Mr. Ramesh Kumar
- \* Mr. Ahmed Al-Rawaji

### Madinah & Northern Region

- \* Dr. Amal Al-Behani- Director
- \* Mr. Abdullah Al Subaihi
- \* Mr. Abu Maali Ibrahim
- \* Mr. Yousef Abdulhadi (CTR)
- \* Mr. Akram Zamzami

### Southern Region

- \* Dr. Abdurahman Al-Shehri- Director
- \* Mr. Syed Zafar Iqbal
- \* Mr. Saleh Al-Olyani



## **ARABIC SUMMARY**

السرطانات العشرة الأكثر شيوعاً بين السعوديين في كلا الجنسين

اناث	٦٣٦٤	%	ذكور	٥٢٨١	%
الثدي	١٨٥٢	٢٩,١	القولون والمستقيم	٧٣٦	١٣,٩
الغدة الدرقية	٧٠٢	١١,٠	اللفافوي اللاهوجكن	٤٣٥	٨,٢
القولون والمستقيم	٦٥١	١٠,٢	ابيضاض الدم	٤٠٢	٧,٦
اللفافوي اللاهوجكن	٣١١	٤,٩	الكبد	٣٣٩	٦,٤
الرحم	٢٨٩	٤,٥	الرئة	٣٢٦	٦,٢
ابيضاض الدم	٢٨٢	٤,٤	البروستات	٣٠٦	٥,٨
المبيض	١٩٤	٣,٠	اللفافوي هودجكن	٢٣٩	٤,٥
الكبد	١٥٦	٢,٥	المثانة	٢٢٧	٤,٣
اللفافوي هودجكن	١٥٤	٢,٤	المعدة	١٩٥	٣,٧
الدماغ	١٢٨	٢,٠	الكلية	١٩٣	٣,٧

السرطانات العشرة الأكثر شيوعاً بين البالغين السعوديين في كلا الجنسين

اناث	٦٠٥٣	%	ذكور	٤٨٧٤	%
الثدي	١٨٥٢	٣٠,٦	القولون والمستقيم	٧٣٥	١٣,١
الغدة الدرقية	٦٩٣	١١,٤	اللفافوي اللاهوجكن	٣٩٨	٨,٢
القولون والمستقيم	٦٤٨	١٠,٧	الكبد	٣٣٣	٦,٨
اللفافوي اللاهوجكن	٣٠١	٥,٠	الرئة	٣٢٣	٦,٦
الرحم	٢٨٩	٤,٨	البروستات	٣٠٥	٦,٣
المبيض	١٨٩	٣,١	ابيضاض الدم	٢٥٠	٤,٩
ابيضاض الدم	١٥٦	٢,٦	المثانة	٢٢٣	٤,٦
الكبد	١٥٣	٢,٥	اللفافوي هودجكن	٢٠٠	٤,١
اللفافوي هودجكن	١٣٨	٢,٣	المعدة	١٩٥	٤,٠
المعدة	١٢١	٢,٠	الغدة الدرقية	١٨١	٣,٧

السرطانات العشرة الأكثر شيوعاً بين الأطفال السعوديين في كلا الجنسين

اناث	٣٠٩	%	ذكور	٢٥٥	%
ابيضاض الدم	١٢٦	٤٠,٨	ابيضاض الدم	١٥٢	٥٩,٦
الدماغ والجهاز العصبي	٣٨	١٢,٣	الدماغ والجهاز العصبي	٥٩	٢٣,١
الكلية	٢٠	٦,٥	اللفافوي هودجكن	٣٩	١٥,٣
العظام	١٨	٥,٨	اللفافوي اللاهوجكن	٣٧	١٤,٥
الانسجة الضامة	١٦	٥,٢	الكلية	٢٤	٩,٤
اللفافوي هودجكن	١٦	٥,٢	العظام	٢٣	٩,٠
العين	١٣	٤,٢	الانسجة الضامة	١٣	٥,١
الغدة الكظرية	١١	٣,٦	العين	١٢	٤,٧
اللفافوي اللاهوجكن	١٠	٣,٢	الغدة الكظرية	١٠	٣,٩
الغدة الدرقية	٩	٢,٩	الكبد	٦	٢,٤

## إحصائيات السرطان في المملكة العربية السعودية لعام ٢٠١٣ م

أنشئ السجل السعودي للأورام في عام ١٤١٢ هـ (١٩٩٢م) بمستشفى الملك فيصل التخصصي ومركز الأبحاث تحت إشراف وزارة الصحة وبمشاركة من القطاعات الصحية الحكومية. يضم السجل خمسة فروع في مناطق المملكة بالإضافة إلى وجود مكاتب في كلاً من مستشفى الملك فيصل التخصصي ومركز الأبحاث بالرياض ومدينة الأمير سلطان الطبية العسكرية ومدينة الملك عبد العزيز الطبية بجدة ومستشفى قوى الأمن بالرياض ومستشفى الملك خالد الجامعي بالرياض. بدأ السجل نشاطه في جمع المعلومات من شهر يناير في عام ١٩٩٤م، حيث يتم جمع وترميز البيانات وتدخل حسب النظام المعتمد من منظمة الصحة العالمية وتحلل البيانات بشكل دوري. كما أن السجل يقوم بتزويد الجهات المختصة والباحثين بمعلومات إحصائية مفصلة بناء على طلبهم وفق نموذج خاص على صفحة السجل في الموقع الرسمي للمجلس الصحي السعودي:

<http://www.chs.gov.sa/En/HealthRecords/CancerRegistry/Pages/RequestForm.aspx>

بلغ إجمالي عدد حالات السرطان المسجلة في عام ٢٠١٣ م ما مجموعه ١٥٠٠١ حالة، من بين هذه الحالات ١١٦٤٥ سعودي بنسبة ٧٧,٦٪ و غير سعوديين ٣٣٥٦ بنسبة ٢٢,٣٪، من بين السعوديين حالة ٥٢٨١ ذكور بنسبة ٤٥,٣٪ والإناث ٦٣٦٤ حالة بنسبة ٥٤,٧٪.

سعوديين			غير سعوديين			المجموع الكلي
ذكر	أنثى	المجموع	ذكر	أنثى	المجموع	
٥٢٨١	٦٣٦٤	١١٦٤٥	١٧٥٩	١٥٩٧	٣٣٥٦	١٥٠٠١

بلغ المعدل المعياري للإصابة بالسرطان في كل ١٠٠,٠٠٠ من السكان (بين الرجال ٧٨,٥/١٠٠,٠٠٠ وبين النساء ٨٩,٤/١٠٠,٠٠٠).

### السرطانات العشرة الأكثر شيوعاً بين السعوديين في كلا الجنسين

يحتل سرطان الثدي المرتبة الأولى (١٨٧٤ حالة) بنسبة ١٦,١٪ ثم سرطان القولون والمستقيم (١٣٨٧ حالة) بنسبة ١١,٩٪ يليه سرطان الغدة الدرقية (٨٨٤ حالة) بنسبة ٧,٦٪ ثم السرطان اللمفاوي اللاهودجكن (٧٤٦ حالة) بنسبة ٦,٤٪ ثم سرطان ابيضاض الدم (٦٨٤ حالة) بنسبة ٥,٩٪ يليه سرطان الكبد (٤٩٥ حالة) بنسبة ٤,٣٪ يليه سرطان الرئة (٤٣٥ حالة) بنسبة ٢,٧٪ يليه السرطان اللمفاوي هودجكن (٣٩٣ حالة) بنسبة ٣,٤٪ ثم سرطان المعدة (٣١٦ حالة) بنسبة ٢,٧٪ وأخيراً سرطان الكلى (٣١٣ حالة) بنسبة ٢,٧٪.

### السرطانات العشرة الأكثر شيوعاً بين البالغين السعوديين في كلا الجنسين

يحتل سرطان الثدي المرتبة الأولى (١٨٧٣ حالة) بنسبة ١٧,١٪ ثم سرطان القولون والمستقيم (١٣٨٣ حالة) بنسبة ١٢,٧٪ يليه سرطان الغدة الدرقية (٨٧٤ حالة) بنسبة ٨,٠٪ ثم السرطان اللمفاوي اللاهودجكن (٦٩٩ حالة) بنسبة ٦,٤٪ ثم سرطان الكبد (٤٨٦ حالة) بنسبة ٤,٤٪ يليه سرطان الرئة (٤٣٢ حالة) بنسبة ٤,٠٪ يليه سرطان ابيضاض الدم (٤٠٦ حالة) بنسبة ٣,٧٪ ثم سرطان اللمفاوي هودجكن (٣٣٨ حالة) بنسبة ٣,١٪ ثم سرطان المعدة (٣١٦ حالة) بنسبة ٢,٩٪ وأخيراً سرطان البروستات (٣٠٥ حالة) بنسبة ٢,٨٪.

### السرطانات العشرة الأكثر شيوعاً بين الأطفال السعوديين في كلا الجنسين

يحتل سرطان ابيضاض الدم المرتبة الأولى (٢٧٨ حالة) بنسبة ٣٨,٨٪ يليه سرطان الدماغ والجهاز العصبي (٩٧ حالة) بنسبة ١٣,٥٪ ثم سرطان اللمفاوي هودجكن (٥٥ حالة) بنسبة ٧,٧٪ ثم السرطان اللمفاوي اللاهودجكن (٤٧ حالة) بنسبة ٦,٦٪ ثم سرطان الكلى (٤٤ حالة) بنسبة ٦,١٪ يليه سرطان العظام (٤١ حالة) بنسبة ٥,٧٪ ثم سرطان الانسجة الضامة (٢٩ حالة) بنسبة ٤,١٪ يليه سرطان العين (٢٥ حالة) بنسبة ٣,٥٪ يليه سرطان الغدة الكظرية (٢١ حالة) بنسبة ٢,٩٪ وأخيراً سرطان الغدة الدرقية (١٠ حالة) بنسبة ١,٤٪.



المملكة العربية السعودية  
المجلس الصحي السعودي  
السجل السعودي للأورام

تقرير معدل الإصابة بمرض السرطان  
٢٠١٣

حرر في يونيو ٢٠١٦